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Abstract 
 
This study investigates the effects of chronic high-fat diet (HFD) and 
endurance training on Non-Alcoholic Fatty Liver Disease (NAFLD) and glycemic 
control. Here we report that chronic HFD promotes hepatic steatosis to an extent, 
which impairs whole body glucose metabolism. Moreover, we illustrate the 
effectiveness of exercise in attenuating HFD-induced NAFLD. In addition to 
NAFLD treatment, exercise improves whole body glycemic control and insulin 
sensitivity. Measures of gluconeogenic markers indicate a reduction in 
gluconeogenesis (GNG) to be partially attributable to the improved glucose 
regulation. Importantly, we present the novel finding that chronic endurance 
exercise reduces the rate of hepatic glycogen synthesis despite improvements in 
glycemia. Thus, it appears glucose has alternate metabolic fates in the body 
which forces mobilization rather than storage of glucose in a trained system. 
Taken together, it appears exercise is an effective therapeutic tool, which can 
significantly improve the deleterious effects of chronic HF-feeding.  
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1. Introduction 
 
The obesity epidemic, which once was a western crisis, has evolved into a 
global concern. As a result, an alarming number of people are spending more of 
their lives in a morbidly obese state (1). Fast food chains whose products 
typically consist of excessive fats and are hyper-caloric in nature are spreading 
rapidly even in several underdeveloped nations. Moreover, modern societies are 
heavily built around technology, and focus on automotive transportation while 
neglecting cyclers, and pedestrians alike (2). As a result, people take this as an 
invitation to welcome a sedentary lifestyle making it difficult for them to meet the 
Canadian recommended guidelines for physical activity of 150min/week (3).  
In 2008 it was estimated that globally, 1.46 billion adults were overweight 
in addition to another 502 million obese adults (4). These obesity trends go hand 
in hand with type 2 diabetes (T2D) and NAFLD. In fact, NAFLD is seen in over 
65% of people with T2D and over 90% of morbidly obese patients (5). Patients 
with NAFLD display excessive hepatic fat accumulation that exceeds 5% of the 
liver’s weight. Due to the lack of signs/symptoms, this liver pathology often goes 
undetected unless scanned for using ultrasound or diagnosed through liver 
biopsy (6). Despite being a silent condition, the effects of NAFLD are suffered at 
both a hepatic and systemic level.  
Individuals with NAFLD often display poor glucose and lipid metabolism. 
This can often further aggravate an already impaired system, as is the case with 
diabetics. A study by Kelley et al., found that patients who were diabetic but also 
had fatty liver were significantly more insulin resistant than those with diabetes 
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alone (7). Moreover, it has been reported that the production of both fat and 
glucose is elevated in these individuals while removal of these substrates is 
impaired or insufficient (8–10). Lastly, in its later stages, NAFLD can end in 
hepatocellular carcinoma and resultant liver failure (11). Therefore, treating this 
condition in its early stages is critical to prevent further morbidities and possible 
mortality.  
Aside from bariatric surgery, which is limited almost exclusively to patients 
in the later stages of NAFLD or severe obesity, there are no therapeutic 
alternatives to treat fatty liver thus far. Therefore, healthcare professionals have 
turned to dietary interventions in conjunction with regular exercise as the primary 
means to reduce fat accumulation in the liver. Reducing both dietary fats and 
overall caloric intake is believed to prevent or in some cases reverse fatty liver. 
Interestingly, a reduction in ectopic fat accumulation following chronic endurance 
exercise has been reported in rats fed a high-fat diet (HFD) (12, 13). 
 Accordingly, this study investigates the effects of chronic high fat feeding 
and endurance training on NAFLD and glycemic control. We analyze numerous 
indicators of glucose and lipid metabolism as well as measure intra-hepatic fat 
content as a means of identifying fatty liver.  
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2. Literature Review 
2.1 Liver 
 
The liver is arguably the most versatile organ in the body. It is crucial for 
the elimination of toxins, production of bile, and maintenance of blood glucose 
homeostasis among other roles. It is a highly perfused organ consisting of two 
blood supplies. Given its close proximity to the intestines, the liver receives 
nutrient rich blood through the portal vein (75% of blood supply). On the other 
hand, it receives oxygen-rich blood through the hepatic artery (25% of blood 
supply). Upon delivering nutrients and oxygen to the liver, blood exits the liver 
through the hepatic vein and returns to the heart.  
Subsequent to an overnight fast, many of the hormones including insulin 
are at their basal levels (14). During this time, the liver is responsible for 
maintaining blood glucose levels within a range of 4-7mM despite not having any 
incoming carbohydrates. It is crucial that this process occurs as organs and cells 
such as the brain and red blood cells rely almost exclusively on glucose as a fuel 
substrate. As such, the liver has two primary means of maintaining plasma 
glucose in a fasted state. First, it may undergo a catabolic process known as 
glycogenolysis to liberate glucose molecules from glycogen. This accounts for 
about 75% of the glucose in circulation under basal conditions. Next, the liver is 
also able to actively produce glucose through non-carbohydrate sources 
including lactate, alanine, pyruvate and glycerol. The de novo synthesis of 
glucose, which occurs almost exclusively in the liver, is known as 
gluconeogenesis (GNG) and accounts for the remaining 25% of circulating 
glucose during prolonged fasting (14).  
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In a fed state, the liver remains the principal site of glucose disposal while 
muscle and adipose tissue represent comparatively minor sites. Under these 
conditions, hepatic plasma insulin concentrations are 3-10 fold higher than in 
circulation in an attempt to minimize post-prandial elevations in blood glucose 
(14). This facilitates a number of processes including uptake of glucose into 
peripheral tissues, the storage of glucose as glycogen, and the suppression of 
GNG and glycogenolysis. Upon receiving a bolus of glucose, nearly 60% of it are 
stored within the liver, 15% is used by muscle and adipose tissue in an insulin-
dependent manner, while the remaining 25% is used to meet the energy 
demands of the brain and other tissues where insulin is not necessary for 
glucose uptake. Interestingly, this 25% is thought of as a glycogen sparing 
mechanism because the body no longer needs to break down existing glycogen 
to meet the energy demands of glucose dependent tissues and cells (14).  
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2.2 Hepatic Glucose Metabolism  
2.2.1 Glycogen Synthesis  
After a meal, the liver uptakes a large quantity of glucose through its 
insulin-independent glucose transporter 2 (GLUT2) and promotes the storage of 
glucose as glycogen. Although it is able to uptake glucose in the absence of 
insulin, the conversion of glucose to glycogen is partly an insulin-mediated 
process (15, 16).  
Given the importance of the liver in glycemic control, glucose absorbed by 
the intestines immediately enters the liver through the portal vein. The liver 
absorbs a large quantity of glucose and any excess glucose exits from the 
hepatic vein. The hepatic vein merges into the inferior vena cava, which returns 
to the heart. This blood is re-oxygenated in the lungs, and re-circulated out the 
aorta. The descending portion of the aorta branches off to supply the oxygenated 
blood to various organs including the liver (through the hepatic artery) and the 
pancreas. Upon sensing the concentration of glucose in the blood, the β-cells of 
the pancreas release insulin. This insulin-rich blood enters hepatic circulation 
through the portal vein upon which the liver can undertake several insulin-
mediated processes including the incorporation of glucose into glycogen.  
 Once insulin reaches the liver, it binds to the insulin receptor and 
promotes autophosphorylation of the receptor. As a result, the insulin receptor is 
able to interact with insulin receptor substrates (IRS), namely IRS-1 and 
phosphorylate these proteins at multiple tyrosine residues. Phosphorylated IRS-1 
interacts with the p85 regulatory subunit of phosphoinositide 3-kinase (P13K) and 
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recruits the catalytic p110 subunit to the plasma membrane. This serves to 
phosphorylate phosphatidylinositol 4,5-bisphosphate (PIP2) that is anchored to 
the lipid bilayer of the cell membrane by two fatty acids. Additional 
phosphorylation of PIP2 forms phosphatidylinositol (3,4,5) trisphosphate (PIP3), 
which activates phosphoinositide-dependent kinase-1 (PDK1) and ultimately 
phosphorylates and activates AKT, also known as Protein Kinase B (PKB). 
Phosphorylation of AKT at Ser473 promotes the subsequent phosphorylation and 
inactivation of glycogen synthase kinase 3 (GSK3); a protein which otherwise 
phosphorylates and inhibits glycogen synthase (GYS) activity (17). GSK3 is 
present in both α and β isoforms and its phosphorylation on an N-terminal 
regulatory site (namely Ser21 and Seri9 on α and β, respectively) remove its 
inhibitory effects on GYS. Insulin simultaneously promotes activity of Protein 
Phosphatase 1 (PP1). Activated PP1 dephosphorylates the Ser641 (Site 3a) 
residue on the COOH-terminal of GYS in an insulin-dependent manner. 
Dephosphorylated GYS is active and therefore results in the incorporation of 
glucose 6-phosphate (G6P) into glycogen (15, 18). 
Although glycogen synthesis is in part an insulin-mediated process in the 
liver, current literature indicates that hepatic glycogen synthesis is largely 
dependent on substrate availability rather than hormonal influence (19). Hence, 
activation of GYS is believed to be proportional to blood glucose concentration, 
while the presence of insulin simply facilitates the process to a smaller extent 
(19). As a consequence, under normal conditions a large portion of the glucose 
entering the liver is used to replete glycogen stores and a smaller fraction is 
diverted towards lipogenesis, glycolysis, and oxidation (15).  
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Figure 1. Schematic of insulin-mediated hepatic glycogen synthesis. Insulin 
binds to its receptor leading to autophosphorylation of the receptor. This 
promotes the interaction of the insulin receptor with the insulin receptor substrate 
1 (IRS1) which is then phosphorylated at its tyrosine residue. Subsequently, 
phosphatidylinositol 4,5-bisphosphate (PIP2) is converted to phosphatidylinositol 
(3,4,5) trisphosphate (PIP3) through phosphoinositide 3-kinase (P13K)-mediated 
phosphorylation. PIP3 activates phosphoinositide-dependent kinase-1 (PDK-1), 
which promotes phosphorylation of AKT at Ser473. Activated AKT phosphorylates 
glycogen synthase kinase 3α (GSK3α) at Ser21 to shut down the inhibitory effect 
of GSK3α on glycogen synthase (GYS). Through a series of reactions, insulin 
concomitantly activates PP1, which dephosphorylates GYS on the Ser641 residue, 
allowing GYS to actively convert G6P to glycogen.  
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2.2.2 Regulation of Glycogen Synthesis 
GYS is the rate-limiting enzyme of glycogen synthesis and is present in 
two known isoforms; glycogen synthase 1 (GYS1) and glycogen synthase 2 
(GYS2). These isoforms are found in muscle and liver, respectively and are 
known to be regulated by both allosteric and covalent mechanisms (19, 20). 
Allosteric regulation involves the binding of an “effector” (e.g. G6P) to a site other 
than the active site of the enzyme. This binding results in a conformational 
change of the protein, thereby modifying its activity. This regulatory mechanism 
elicits a rapid response to high substrate concentrations since it does not rely on 
hormonal signaling. With respect to GYS, high intracellular concentrations of G6P 
are known to allosterically activate this enzyme (19). On the other hand, covalent 
regulation involves the covalent attachment/removal of a molecule (e.g. 
phosphate group) to an enzyme, usually in response to a hormonal signal. 
Likewise, this in turn leads to conformational changes that alter the activity of the 
enzyme.  Covalent regulation of GYS occurs through kinases or phosphatases 
which inhibit and promote GYS activity respectively (21). These include PKA, 
AMP-activated protein kinase (AMPK), GSK3, and PP1.  
 The rate of incorporation of glucose into glycogen in the liver is directly 
correlated with GYS2 activity (19). High G6P concentrations have been shown to 
override covalent modification and activate GYS2 through allosteric mechanisms. 
Given the blunted rate of glycogen synthesis in patients with diabetes and liver 
pathologies, there has been an increased focus on methods to promote GYS 
activity. These patients often see impaired GYS regulation due to their inability to 
respond to insulin. However, the challenge lies behind activating GYS without 
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compromising alternate metabolic pathways such as glycogenolysis, which is 
critical when glucose availability is scarce.  
For instance, one approach to promoting allosteric activation of GYS has 
been to increase the intracellular concentration of G6P by increasing glucokinase 
(GK) content and activity. This enzyme phosphorylates incoming glucose to form 
G6P. It has been reported that in both fasted and fed animals, overexpression of 
GK results in significantly higher glucose phosphorylation in the liver. In fed 
animals, higher doses of GK overexpression resulted in significant reduction in 
circulating glucose and greater than 65% reduction in circulating insulin 
concentrations. Despite effectively clearing glucose from the blood, the rate of 
glycogen synthesis was not measured and no difference in glycogen content was 
found in the fed state (22). Therefore, the fate of G6P in this study is uncertain. 
To this end, primary hepatocytes overexpressing GK have shown significant 
increases in glycogen synthesis. Despite being successful in glucose clearance 
from the blood, overexpression of GK increases circulating triglycerides (TAG) 
and non-esterified fatty acids (NEFA) by 190% and 310%, respectively (22). 
Therefore, the elevated levels of NEFA and TG negate the benefits of improved 
glycemia.   
  Another kinase, which has importance in GYS activity in the liver, is 
AMPK. AMPK activity has also been studied extensively as a covalent regulatory 
mechanism. It is an energy-sensing protein that is activated under conditions of 
low energy levels to promote energy production pathways while inhibiting 
anabolic processes. Moreover, it is involved in a number of metabolic pathways 
including lipid/protein synthesis, cell growth, and mitochondrial biogenesis (23). 
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Isolated hepatocytes from overnight fasted rats have been incubated with AICAR 
(a known pharmacological activator of AMPK) and glucagon (a known activator of 
glycogenolysis) to study GYS activity. Glucagon elicited rapid (within 5 min) 
inactivation of GYS2 and activation of glycogen phosphorylase (GP) activity. On 
the other hand, AICAR induced AMPK activation and led to more gradual 
phosphorylation of GYS2 at Ser7 (site 2) on the NH2-terminal and a concomitant 
increase in glycogen phosphorylase (GP) activity (24). The same group went 
further and studied mice lacking the α1 and α2 catalytic subunits of AMPK 
(AMPKα1/α2-KO) in an attempt to investigate the contribution of AMPK to GYS 
activity. Basal GYS activity of AMPKα1/α2-KO mice was 2-times greater than in 
their wild-type counterparts. However, treatment of these mice with glucagon 
revealed a similar reduction of GYS activity compared to WT. These results 
suggest a possible pharmacological target of liver specific AMPK activity to 
promote glycogen synthesis.  
Recent studies have attempted to target proteins immediately involved in 
the glycogen synthesis pathway rather than targeting upstream proteins with less 
specificity. As such, the interest in direct GYS regulation has sparked a lot of 
attention given that it is the terminal enzyme of glycogen synthesis. Accordingly, 
another approach to facilitating glucose clearance and storage has been to 
induce hepatic overexpression of a constitutively active form of glycogen 
synthase. When studying the ability to clear glucose from the blood using a 
intraperitoneal glucose tolerance test (IPGTT), rats with mutated phosphorylation 
sites 2 and 3B on GYS were significantly better at clearing glucose from the 
blood and had a 30% smaller AUC compared to wild type (25). Rats expressing 
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constitutively active GYS had a two-fold increase in glycogen content under fed 
states compared to their wild type counterparts (25). This finding suggests that 
the limiting factor to glycogen synthesis is not the storage capacity or number of 
enzymes itself, but rather the activation state of existing enzymes. Moreover, 
they had less glycogen stores when fasted compared to their fed state indicating 
the mobilization of glycogen under fasting conditions despite having the mutated 
GYS. This approach has been deemed successful in lowering blood glucose in 
fed states (25). Additionally, rats with mutated GYS showed no difference in 
circulating insulin, lactate, NEFAs, or TAGs.  
2.2.3 Glycogenolysis  
The storage of glycogen is a process that not only minimizes the elevation 
of blood glucose levels, but also prepares the system for fasting conditions. 
When glucose availability is scarce, and circulating insulin levels are low, 
glycogen stores can be mobilized through glycogenolysis to normalize plasma 
glucose concentrations. Normally, this contributes to ~ 75% of resting blood 
glucose (14). However, in the case of diabetes and insulin resistance, this 
mechanism becomes a deregulated and ongoing event contributing to a 
hyperglycemic state.   
Normally, upon fasting or during an exercise stimulus, both glucagon and 
epinephrine are elevated to mobilize glycogen stores and normalize blood 
glucose concentrations. Although both are important mediators of glycogenolysis 
in muscle, glucagon; the counter-regulatory hormone to insulin is the major 
stimulator of glycogen breakdown in the liver with epinephrine having a 
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potentiating effect. Once a ligand binds to a G-Protein coupled receptor (GPCR) 
(i.e. β-Adrenergic and glucagon receptors for epinephrine and glucagon, 
respectively) the GPCR undergoes a conformational change. As a result, the α 
subunit of the GPCR exchanges GDP for GTP and dissociates from the GPCR to 
migrate to and activate adenylate cyclase. Activated adenylate cyclase uses 
adenosine triphosphate (ATP) to produce cyclic adenosine monophosphate 
(cAMP), which acts as a second messenger to activate protein kinase A (PKA). 
Elevated cAMP aids in dismantling the tetrameric inactive PKA (consisting of 2 
catalytic and 2 regulatory subunits) and freeing the catalytic subunits. Activation 
of PKA leads to the subsequent phosphorylation and activation of phosphorylase 
kinase (PK). Ultimately, phosphorylase kinase phosphorylates and activates 
glycogen phosphorylase (GP), which catalyzes the breakdown of glycogen into 
glucose 1-phosphate (G1P) monomers (26). 
The rate of glycogen breakdown is in part dependent on the activity of 
glycogen phosphorylase, which similar to GYS, appears to involve covalent and 
allosteric regulatory mechanisms. In a fed state, high circulating insulin inhibits 
glycogen catabolism in an attempt to minimize elevations in postprandial 
glycemia. Through a series of reactions, insulin activates Protein Phosphatase 1 
(PP1), which subsequently dephosphorylates and inactivates glycogen 
phosphorylase (27). Moreover, insulin also activates Phosphodiesterase (PDE), 
which converts cAMP to AMP, thereby removing the second messenger 
mediated signaling for glycogenolysis. Glycogen metabolism is thus a tightly 
regulated process influenced by a number of hormones and substrates 
depending on the nutritional status of the system (26).   
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Figure 2. Schematic of glucagon/epinephrine-mediated glycogenolysis. A ligand 
(glucagon/epinephrine) binds to the G-Protein Coupled Receptor (GPCR) leading 
to a conformational change of the receptor. Subsequently, the α subunit is 
activated upon exchanging its guanosine diphosphate (GDP) for guanosine 
triphosphate (GTP). The α subunit migrates towards and activates adenylate 
cyclase (AC). AC converts adenosine triphosphate (ATP) to the second 
messenger cyclic adenosine monophosphate (cAMP) which serves to activate 
Protein Kinase A (PKA). Activated PKA phosphorylates phosphorylase kinase 
(PK), which subsequently phosphorylates glycogen phosphorylase (GP). 
Activated GP catalyzes the breakdown of glycogen into glucose 1-phosphate 
(G1P).  
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2.2.4 Gluconeogenesis (GNG) 
 Given the importance of the liver in blood glucose regulation, it is 
imperative that tightly regulated mechanisms are in place to maintain euglycemia 
in a state of fasting and post-glycogen depletion. In times when glucose 
availability is inadequate, the body is able to synthesize glucose from non-
carbohydrate sources including lactate, pyruvate, alanine, and glycerol. This de 
novo synthesis of glucose is referred to as gluconeogenesis (GNG), a process 
that occurs almost exclusively in the liver. GNG is usually activated 4-6 hours 
after the onset of fasting and is at its maximal output upon complete depletion of 
glycogen stores (28). De novo production of glucose is primarily stimulated by 
glucagon and catecholamines while being inhibited by insulin.  
2.2.4.1 Mechanism of GNG 
 
 The mechanism by which the liver produces glucose involves the 
reciprocal reactions of glycolysis with the exception of three notable differences 
(Figure 3). 
1. Oxaloacetate (OAA) à Phosphoenolpyruvate (PEP) 
2. Fructose 1-6 Bisphosphate (FBP) à Fructose 6 Phosphate (F6P) 
3. Glucose 6-Phosphate (G6P) à Glucose 
As a result of these differences, the glycolytic enzymes pyruvate kinase, 
phosphofructokinase, and hexokinase/glucokinase are replaced with 
phosphoenolpyruvate carboxykinase (PEPCK), fructose-1,6-bisphosphatase 
(FBPase) and glucose-6-phosphatase (G6Pase) respectively . 
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Under conditions of low circulating insulin and elevated glucagon or 
catecholamines, the liver actively converts any circulating lactate or alanine into 
pyruvate within the mitochondria. The resulting pyruvate is converted to OAA by 
pyruvate carboxylase (PC). The subsequent decarboxylation and 
phosphorylation of OAA by PEPCK is the first difference between glycolysis and 
GNG. In certain species, which lack mitochondrial PEPCK, OAA needs to be 
shuttled out of the mitochondria where it is converted to PEP by cytosolic 
PEPCK. Given that such transport mechanisms fail to exist for OAA, it is reduced 
to malate within the mitochondria. Malate is shuttled out through the malate 
aspartate shuttle (MAS) and oxidized back to OAA in the cytoplasm. In this case, 
OAA becomes a substrate for cytoplasmic PEPCK (PEPCK-C), an energy 
consuming process in the form of GTP. The resulting phosphoenolpyruvate 
(PEP) becomes 2-Phosphoglycerate (2-PG) with the help of enolase. 2-PG 
proceeds further into the GNG pathway and forms 3-Phosphoglycerate (3-PG); a 
reaction catalyzed by phosphoglycerate mutase (PGAM). Next, intracellular 3-PG 
forms 1,3-BPG with the help of phosphoglycerate kinase (PGK).  The resulting 
1,3 BPG is a substrate for the enzyme glyceraldehyde phosphate dehydrogenase 
(GAPDH) to produce glyceraldehyde 3-phosphate (G3P). Subsequently, G3P 
yields fructose 1-6 bisphosphate in a reaction catalyzed by aldolase.  
The second difference lies in the conversion of fructose 1-6-bisophosphate 
to fructose 6-phosphate by removal of a phosphate group on its first carbon; 
catalyzed by fructose 1-6 biphosphatase. Then, phosphohexoisomerase (PHI) 
catalyzes the reversible reaction of fructose 6-phosphate to G6P (15).  
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The final distinction and rate-limiting step of this pathway lies in the 
conversion of G6P to glucose by G6Pase. This step removes a phosphate group 
from G6P, which was originally incorporated by glucokinase. As a result, glucose 
is no longer bound intracellularly and is free to exit the cell and find its way to 
extrahepatic tissues.  
Unlike pyruvate, lactate, and alanine, glycerol enters the GNG pathway at 
a later stage. Glycerol is converted to G3P by glycerol kinase (GLYK), after which 
it will undergo the same fate as the other precursors in the synthesis of glucose.  
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Figure 3. Schematic of the gluconeogenic pathway. Lactate and alanine are 
converted to pyruvate by lactate dehydrogenase (LDH) and alanine transaminase 
(ALT) respectively. Pyruvate and malate (shuttled out of the mitochondria by the 
malate aspartate shuttle (MAS)) become Oxaloacetate (OAA) by malate 
dehydrogenase (MDH) and pyruvate carboxylase (PC) respectively. OAA 
proceeds up the GNG pathway through the reverse reactions of glycolysis with 
the exception of three reactions. 1) OAA to phosphoenolpyruvate (PEP), 2) 
fructose 1,6-bisphosphate (FBP) to fructose 6-phosphate (F6P), and  3) glucose 
6-phosphate (G6P) to glucose are catalyzed by phosphoenolpyruvate 
carboxykinase (PEPCK), fructose 1,6-bisphosphatase (FBPase), and glucose 6-
phosphatase (G6Pase) respectively. Glycerol enters in the later stages of GNG 
and is converted to glyceraldehyde 3-phosphate (G3P) by glycerol kinase 
(GLYK). Other abbreviations include 2-phosphoglycerate (2-PG), 
phosphoglycerate mutase (PGAM), 3-phosphoglycerate (3-PG), 
phosphoglycerate kinase (PGK), 1,3-bisphosphoglycerate (1,3 BPG), 
glyceraldehyde phosphate dehydrogenase (GAPDH), fructose 1,6-bisphosphate 
(FBP), and phosphohexoisomerase (PHI).  
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2.2.4.2 Peroxisome proliferator-activated receptor (PPAR)-γ co-activator-1α (PGC-
1α) 
 
PGC-1α is a transcriptional co-activator and has various tissue dependent 
effects. It has been shown to be crucial for mitochondrial biogenesis in muscle, 
and thermogenesis in brown adipose tissue, whereas in the liver the primary role 
of PGC-1α is to regulate the expression of gluconeogenic genes (29, 30). 
Importantly, it has been reported that the activity of PGC-1α is deregulated in 
both NAFLD as well as diabetes (29–32). In the presence of low circulating 
insulin or insulin resistance, PGC-1α expression is increased. Conversely, when 
circulating insulin is high (in a fed state), the expression of PGC-1α is rapidly 
reduced. The mechanism behind PGC-1α regulation is not completely 
understood. It appears that an elevation in glucagon and glucocorticoids may 
directly promote PGC-1α expression. Along the same lines, it has been 
suggested that elevations in insulin directly inhibit the effects of glucagon on the 
PGC-1α promotor region. Despite this, although PGC-1α is important for GNG, 
this protein requires a number of transcription factors to be present in order to 
elicit its effects (28, 33, 34). 
 Yoon et al, provided important mechanistic insight into the role of PGC-1α 
in GNG. By treating mice with streptozotocin (STZ), they were able to mimic the 
physiological parameters of type 1 diabetics. These mice show constantly 
elevated hepatic expression of PGC-1α, consistent with the view that the content 
of this protein is increased under conditions of insulin deficiency (35). The same 
group used a fasting/re-feeding model to demonstrate that the increased hepatic 
PGC-1α expression in the fasted state is followed by elevated PEPCK and G6P 
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content shortly after; supporting the notion that PGC-1α expression precedes the 
activation of gluconeogenic genes in the liver. Conversely, re-feeding resulted in 
a down regulation of PGC-1α expression and a concomitant reduction in hepatic 
PEPCK/G6P content (31). 
 In contrast to their insulin-centered experiments, the same group went 
further to investigate the glucagon/epinephrine mediated effects on PGC-1α. 
Normally, hepatic cAMP is elevated in the fasted state. Moreover, it has been 
shown that cAMP acts through β-adrenergic receptors to promote PGC-1α 
expression in brown fat where it is crucial for the thermogenic properties of brown 
fat (36). Under the same principle, primary hepatocytes were stimulated by 8-
bromo-cAMP, a cAMP analogue. This study found that stimulation by 8-bromo-
cAMP elicited a large increase in PGC-1α mRNA (31). As such, elevations in 
cAMP in a fasted state promotes the expression of PGC-1α mRNA. This is one 
mechanism behind elevated GNG upon fasting.  
2.2.4.3 PEPCK 
 
 Phosphoenolpyruvate Carboxykinase (PEPCK) is a rate-limiting enzyme in 
GNG and is largely present in hepatocytes in both mitochondrial (PEPCK-M) and 
cytosolic (PEPCK-C) isoforms. Although humans possess relatively equal 
amounts of both isoforms, rodents express up to 90% PEPCK-C, which limits the 
research in these animals almost entirely to this isoform (37, 38). As illustrated by 
Hanson et al., liver-specific as well as whole-body PEPCK knockout mice elicit 
severe hypoglycemia and even death in as little as two days after birth. 
Moreover, mice lacking PEPCK had 2-3-fold more hepatic triglyceride content 
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and 50% more circulating triglycerides compared to controls (38). This increase 
in triglycerides has been attributed to a 10-fold increase in hepatic malate 
concentration, which disrupts the Krebs cycle. The backup of Krebs cycle 
intermediates promotes a buildup of acetyl-CoA, reduced fat oxidation, and a 
buildup of hepatic triglycerides (38). Therefore, it is clear that proper regulation of 
PEPCK is critical for both GNG and lipid metabolism.   
Unlike proteins in the glycogen synthesis cascade, PEPCK activity is 
regulated at a transcriptional level rather than covalent modification. Under basal 
conditions when insulin levels are low, and glucagon levels are elevated 
(resulting in elevated cAMP), transcription of PEPCK is increased. This results in 
greater conversion of OAA into PEP, which promotes hepatic glucose production. 
Conversely, in a fed state, PEPCK activity is suppressed in response to elevated 
insulin and reduced glucagon concentrations (39).  
 Although transcription of PEPCK is regulated through hormones, these 
hormones elicit their effects through a number of transcription factors (e.g. 
Forkhead box protein O1 (FOXO1), Hepatocyte nuclear factor 4α (HNF4α), and 
Peroxisome proliferator-activated receptor α (PPARα)) and the transcriptional co-
activator PGC-1α. These factors serve to promote transcription of GNG genes 
including PEPCK and G6Pase. Transcription factors such as FOXO1 and HNF4α 
bind to the promoter regions adjacent to a specific gene of interest, thereby 
controlling the rate of transcription for that gene. In addition, co-activators such 
as PGC-1α, promote gene expression by binding to transcription factors, as co-
activators are unable to bind directly to the DNA sequence themselves (28, 31, 
33) .   
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 Rhee et al., provided valuable insight into the importance of HNF4α in 
GNG gene transcription. By analyzing RNA taken from either control or liver-
specific HNF4α-KO mice, they found that under fasting conditions, HNF4α-KO 
mice fail to express PEPCK or G6Pase to the same extent seen in control mice. 
Intriguingly, in both fed and fasted states, PGC-1α expression was greater in 
HNF4α-KO than controls. It is not clear whether this is a compensatory 
mechanism resulting from compromised GNG, or whether HNF4α itself plays a 
role in the regulatory mechanisms of PGC-1α that are compromised with HNF4α-
KO. Furthermore, the same group was interested in whether HNF4α is critical for 
PGC-1α to elicit its effects. In this respect, they isolated primary hepatocytes that 
were either controls or KO for HNF4α. Using adenoviral infection of PGC-1α in 
control livers resulted in a concomitant rise in PEPCK and G6Pase expression. 
However, similar mRNA infection of PGC-1α in HNF4α-KO hepatocytes fails to 
express these GNG genes. As a result it is clear that HNF4α plays a critical role 
in the transcription of GNG genes that cannot be carried out by PGC-1α alone 
(28).  
  FOXO1 is another transcription factor involved in GNG that appears to be 
regulated in an insulin-dependent manner. That is, upon insulin binding to its 
receptor, phosphorylated AKT later phosphorylates FOXO1 leading to the 
exclusion of this transcription factor from the nucleus (33, 40). Upon exclusion 
from the nucleus, FOXO1 is unable to engage in gene transcription. However, 
under fasting conditions, or in T2D where insulin action is reduced or impaired 
respectively, reduced phosphorylation of AKT leaves FOXO1 permeable to the 
nucleus. This permits FOXO1 to partake in GNG gene transcription in 
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conjunction with PGC-1α. Yoon et al., used FAO hepatoma cells to study the 
interaction of PGC-1α and FOXO1. FAO hepatoma cells have very little 
endogenous PGC-1α and are therefore a viable model to study this protein using 
adenoviruses. It has been reported that when infected with PGC-1α alone, these 
cells display concomitant rises in G6Pase and PEPCK expression. However, 
when infected with a truncated FOXO1 allele (also a dominant negative 
suppressor of wild type FOXO1) or PGC-1α in conjunction with the truncated 
FOXO1 allele, expression of these GNG genes is heavily compromised. 
Therefore, it appears that the functional interaction of PGC-1α with FOXO1 is 
critical to the induction of GNG genes (33, 40).   
2.2.5 Glucose 6-Phosphate 
 Glucose 6-Phosphate (G6P) is a unique intermediary molecule in glucose 
metabolism because of its versatility in the preservation of glycemic control. Upon 
entering a hepatocyte, glucose is rapidly phosphorylated by GK, which prevents it 
from exiting the cell. The resultant G6P is now readily available for storage in a 
state of hyperglycemia (41). In contrast, G6Pase is capable of reversing the initial 
reaction catalyzed by GK, thus liberating glucose into circulation under conditions 
of hypoglycemia. Therefore, the fate of G6P may be determined by four factors. 
These include the concentration of 1) glucose and 2) G6P available at a cellular 
level and the enzymatic activity of both 3) GK and 4) G6Pase.  
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2.3 Hepatic Lipid Metabolism  
 
 Similar to carbohydrates, lipids represent a crucial source of energy 
particularly under fasting conditions. Given that they contain more than twice the 
energy content of carbohydrates and proteins, lipids are a highly efficient energy 
source. Hepatic regulation of incoming lipids maintains lipid homeostasis as the 
liver packages incoming fats into very-low-density-lipoproteins (VLDL) and 
exports them to peripheral tissues. As the newly synthesized VLDLs circulate 
past muscle and adipose tissues, lipoprotein lipase (LPL) cleaves TAGs 
contained in the VLDL to liberate fatty acids (FA) for oxidation or re-esterification. 
Analogous to how the body stores glucose as glycogen; FAs are preferentially 
stored as triglycerides within the adipose tissue. Under fasted conditions, rates of 
FA oxidation are increased in an attempt to minimize glucose oxidation and 
promote GNG. This ensures that glucose is spared for glucose-dependent 
organs such as brain. However, in a state of glucose abundance, the body 
preferentially oxidizes glucose and suppresses fat oxidation (42). 
2.3.1 Lipogenesis 
 Given that the glycogen stores in both liver and muscle are limited and 
that the liver is the central regulator of glycemia, there are mechanisms in place 
to deal with surplus carbohydrates. Under, these conditions, when circulating 
insulin is elevated, the body converts excess carbohydrates into fat, a process 
known as lipogenesis. Insulin serves to increase the activity of enzymes 
catalyzing lipid synthesis while concomitantly inhibiting those catalyzing lipid 
breakdown (15).   
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 Subsequent to a high carbohydrate diet, the primary means of dealing with 
the abundance of glucose is to store it as glycogen. Any remaining glucose will 
undergo glycolysis, be converted to glycerol 3-phosphate (required for 
esterification of fatty acids to form TAG), or lipogenesis (Figure 4). Once glucose 
enters the cell and undergoes glycolysis within the cytoplasm, the resulting 
pyruvate molecules enter the mitochondria. Pyruvate dehydrogenase (PDH) 
converts pyruvate into acetyl-CoA. Although acetyl-CoA is a precursor of fat 
synthesis, it cannot be used for lipogenesis as long as it remains in the 
mitochondria. Therefore the body must shuttle this molecule across the 
mitochondrial membrane and into the cytoplasm where many of the enzymes 
required for de novo lipid synthesis are located. Given that the mitochondrial 
membrane is impermeable to acetyl-CoA, and there are no active shuttles to 
transport it into the cytoplasm, it enters the Krebs cycle. Once in the Krebs cycle, 
acetyl-CoA (2C) and OAA (4C) fuse to form citrate (6C) in a reaction catalyzed by 
citrate synthase. Unlike acetyl-CoA, citrate can cross the mitochondrial 
membrane and gain access into the cytoplasm, where it will be broken down 
again into OAA and acetyl-CoA. This reaction is catalyzed by ATP-Citrate Lyase 
(ACYL). The resultant cytoplasmic acetyl-CoA is carboxylated in the presence of 
insulin by acetyl-CoA carboxylase (ACC) into malonyl-CoA (43). This newly 
synthesized malonyl-CoA is a potent inhibitor of carnitine palmitoyltransferase I 
(CPT1). Through a series of condensation reactions, which add 2 carbons each 
time to malonyl-CoA, a fatty acid (i.e. palmitate or oleate) is synthesized. This 
reaction occurs with the aid of fatty acid synthase (FAS). The newly synthesized 
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fatty acids are esterified to glycerol phosphate to form TAG. The latter are 
packaged into VLDLs and released into circulation (44, 45).  
Insulin is a potent stimulator of de novo lipogenesis. Moreover, the rate of 
lipogenesis depends largely on the availability and activity of two major enzymes; 
namely ACC and FAS. These enzymes are regulated at the level of transcription, 
depending on nutritional status. Sterol regulatory element-binding protein-1c 
(SREBP-1c) is believed to be the master regulator of gene transcription for 
enzymes involved in the de novo lipid synthesis pathway. In the fed and fasted 
states, SREBP-1c expression is elevated and suppressed respectively (46). To 
illustrate the importance of this transcription factor in lipogenesis, mice with liver 
specific overexpression of SREBP-1c have been studied. Overexpression of this 
factor promotes the development of fatty livers by 24 weeks of age. Moreover, 
these mice display 50% more fatty acids stored in the liver compared to controls. 
This occurred even in mice fed a standard chow (SC) diet. Moreover, SREBP-1c 
overexpression revealed a two-fold increase in FFA and TAG in addition to a 
three-fold increase in insulin in the blood (47).  
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Figure 4 - Schematic of de novo lipogenesis in a liver cell. Upon a high influx of glucose 
into the cell, glucose undergoes glycolysis or forms glycerol phosphate. Pyruvate from 
glycolysis enters the mitochondria and is converted to acetyl-CoA (A-CoA) by pyruvate 
dehydrogenase (PDH). Pyruvate enters the Krebs cycle and exits the mitochondria as 
citrate. Citrate lyase (CL) converts citrate to A-CoA. In the presence of insulin, acetyl-
CoA carboxykinase (ACC) is dephosphorylated and activated. ACC converts A-CoA to 
malonyl-CoA (M-CoA). M-CoA is formed into a fatty acid by fatty acid synthase (FAS). 
This is accomplished by continuously adding 2 carbons through a series of condensation 
reactions. The newly formed fatty acyl-CoA is esterified to glycerol phosphate to yield a 
triglyceride (TAG) (44, 45).   
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2.3.2 Lipid Oxidation 
 Under fasting conditions, or when circulating insulin levels are low and 
glucagon is elevated, the body mobilizes its fat stores within the adipose tissue. 
Stored triglycerides are actively hydrolyzed into FFA, which are then released 
into the bloodstream. These FFA eventually reach the mitochondria, 
peroxisomes, or endoplasmic reticulum of muscle and liver to undergo oxidation. 
Normally, the rate of hepatic FAO is proportional to the plasma concentration of 
FFA released by the adipose tissue (48).  
The oxidation of fatty acids can be thought of as a three step process 
involving 1) Activation, 2) Transport, and finally 3) Oxidation. Aside from some 
short and medium chain fatty acids, long chain fatty acids are impermeable to the 
mitochondrial membrane. As a result, fatty acids are “activated” by converting 
them into acyl-CoA molecules within the cytoplasm. This is catalyzed by the 
enzyme fatty acyl-CoA synthetase (FACS). The resulting long chain acyl-CoA 
molecules are “transported” into the mitochondria, the primary site of β-oxidation, 
by CPT1 (49). This translocase is located on the outer mitochondrial membrane. 
CPT1 fuses the acyl group from acyl-CoA with carnitine to make it transportable 
into the mitochondria. Hence, CPT1 acts as a gatekeeper and is therefore a rate-
limiting transporter in the oxidation of long chain fatty acids (LCFA). Inhibition of 
CPT1 (by malonyl-CoA, an intermediary molecule of lipogenesis) limits fat 
oxidation to short-chain fatty acids, which can freely diffuse through the 
mitochondrial membrane. Once in the mitochondria, fatty acids undergo β-
oxidation resulting in the cleaving of fatty acids into 2-carbon acetyl-CoA 
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molecules. The resulting acetyl-CoA may enter the Krebs cycle to undergo 
further oxidation, or be converted to ketone bodies and which can then enter 
circulation.  
2.4 Regulation of Glucose and Lipid Metabolism  
 
The regulation between lipid and carbohydrate metabolism was first 
described by Philip Randle who stressed the reciprocal regulation of these two 
macromolecules under various nutritional states (50). In a fed state, when 
circulating insulin is high and glucagon levels are low, glucose oxidation is 
promoted while fat oxidation is inhibited. In fact, under these conditions, the 
synthesis of fats from excess glucose involves a concomitant rise in malonyl-CoA 
that is later converted to fatty acids by the ACC/FAS pathway. Elevated malonyl- 
CoA exerts an allosteric inhibitory effect on CPT1 and channels fatty acids 
towards TAG synthesis. This prevents the redundant process of allowing newly 
synthesized acyl-CoA molecules from subsequently undergoing β-oxidation. On 
the other hand, in a fasted state with low insulin and elevated glucagon, malonyl-
CoA levels are down which lifts its allosteric inhibition on CPT1 (50). This allows 
β-oxidation and the liberation of ATP from fatty acids, while concomitantly 
preserving glucose for glucose dependent tissues.  
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2.5 High-Fat Diet  
 
 HFDs (which contain up to 60% of calories from fats in extreme cases), 
particularly those rich in saturated fats are known to induce dyslipidemia, 
hyperinsulinemia, and hyperglycemia. Normally, fats are preferentially stored 
within the white adipose tissue (WAT) in the form of TAG. When feeding a HFD, 
the amount of fat available is so large that it exceeds ability of the WAT to store 
them (51). This results in hepatic lipid accumulation and disrupts normal liver 
function, which severely compromises the ability of this organ to properly 
maintain glucose and lipid homeostasis. It is unclear whether hepatic insulin 
resistance precedes or is a result of excessive accumulation of lipids in the liver 
(52). However, what seems to be well established is that prolonged exposure to a 
HFD leads to several metabolic abnormalities including increased lipolysis, 
impaired glucose disposal, and elevated hepatic GNG and glycogenolysis (40, 
53, 54). 
2.5.1 Mechanism(s) of HFD-induced Hepatic Insulin Resistance  
Although the mechanism(s) underlying the development of hepatic insulin 
resistance is not fully understood, some advances in this field have been made in 
recent years. In this context, the excessive accumulation of lipids in hepatocytes 
as a result of HF feeding has been considered a major factor in the development 
of hepatic insulin resistance.  A well-described mechanism involves the increase 
in the intracellular concentration of diacylglycerols (DAG), which lead to the 
activation of protein kinase C (PKC). The latter is well known for its ability to 
phosphorylate serine residues of IRS-1, which prevents the induction of IRS-1 
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phosphorylation at tyrosine residues by the insulin receptor (55). This leads to 
inhibition of the downstream signaling events by which insulin regulates glucose 
metabolism in the liver. This is well illustrated in mice with liver-specific deletion 
of the PKC gene that display improved insulin sensitivity, despite having elevated 
hepatic lipid content under HF-feeding conditions (56). 
2.5.2 Fatty Acid Induced increase in Gluconeogenesis 
 Chronic HF-feeding has been associated with dyslipidemia and elevated 
circulating NEFAs (57) as a result of insulin resistance (58). This increase in 
circulating NEFAs results in greater delivery of fats to the liver on top of the 
already excessive dietary fats. Moreover, it has been reported that hepatic GNG 
is elevated following chronic HF-feeding (59, 60). The underlying mechanism 
seems to involve an elevation in acetyl-CoA, NADH, and ATP resulting from 
increased fat oxidation. Acetyl-CoA is an allosteric activator of pyruvate 
carboxylase, an enzyme that adds a carboxyl group to pyruvate to form 
oxaloacetate. Oxaloacetate can then be acted on by PEPCK, feeding forward 
into the GNG pathway. Next, higher levels of NADH facilitate the conversion of 1-
3 bisphosphoglycerate to glyceraldehyde 3-phosphate; once again leading 
towards glucose synthesis. Finally, ATP can be used in the energy-dependent 
steps of GNG.  
 Although the expected outcome would be that elevated GNG would also 
increase hepatic glucose output (HGO), the general consensus in the literature is 
that despite FFA increasing GNG within the liver, overall HGO remains 
unchanged in normal humans (61). Hepatic auto regulation is thought to be 
 32 
involved, suggesting that upon sensing elevated GNG, some intra-hepatic 
compensatory mechanism (such as increased glycogen synthesis, reduced 
glycogenolysis, or both) prevents the concomitant rise in HGO (61). However, the 
mechanism by which this occurs is still poorly understood.  
2.6 Non-Alcoholic Fatty Liver Disease (NAFLD) 
 
NAFLD is known throughout the literature to be the hepatic manifestation 
of metabolic syndrome(62), and shown to be a better predictor of metabolic 
abnormalities than visceral adiposity (63). Over 90% of morbidly obese and 65% 
of T2D patients are diagnosed with NAFLD, a condition in which the patient’s 
liver is composed of >5-10% fat (5). It encompasses a spectrum of liver 
pathologies from steatosis, to steatohepatitis, advanced fibrosis, and 
hepatocellular carcinoma. In fact ~ 20% of patients with non-alcoholic 
steatohepatitis (NASH) progress to fibrosis and eventually cirrhosis (6). 
Moreover, histological analysis of these patients’ livers display similar 
characteristics to those of chronic alcohol consumers despite their alcohol intake 
being below the recommended guidelines(9). NAFLD impairs numerous 
metabolic parameters and insulin resistance, diabetes and obesity are significant 
pathophysiological factors in the manifestation of this condition (64).  The fault 
apparently lies largely on the current North American HF and high-calorie diets in 
conjunction with certain advancements in technologies, which have steered both 
adults and children towards a more sedentary lifestyle (65).  
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2.6.1 Pathophysiology of NAFLD 
Although the exact mechanisms involved in the pathogenesis of fatty liver 
disease are not completely understood, it is believed that increased visceral 
adiposity, elevated circulating NEFAs, and insulin resistance following HF feeding 
contribute to its manifestation (52). Due to the abundance in fat availability, 
adipose tissue dysfunction leads to an increase in the secretion of numerous 
inflammatory mediators such as tumor necrosis factor α (TNFα), interleukin 6 (IL-
6), and nuclear factor kB (NFkB) (66, 67). TNFα has been shown to also promote 
serine phosphorylation of IRS-1, which inhibits the insulin-mediated tyrosine 
phosphorylation as previously described (68). Consequently, this leads to 
inhibition of downstream insulin-signaling pathways, which has been shown to be 
reversed in TNFα-KO mice (69). Next, with respect to IL—6, it has been reported 
that primary hepatocytes treated with IL-6 displayed less phosphorylation of AKT 
and a 75% reduction in glycogen synthesis (66).  
Impaired insulin signaling through these inflammatory mediators 
compromise a number of metabolic pathways including lipolysis. Normally, insulin 
elicits an anti-lipolytic effect on adipose tissue, which becomes compromised in 
an insulin-resistant state (55). This results in increased release of NEFAs from 
the adipose tissue and higher delivery of these lipids to the liver(70). Importantly, 
the extra NEFAs released as a consequence of the impaired ability of insulin to 
suppress lipolysis contribute additional lipids to the already excessive amount 
that is incoming through the diet.  Moreover, an elevation of lipogenic 
transcription factors and enzymes including SREBP-1c and FAS (12) have also 
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been reported. These factors have been attributed to increased de novo 
lipogenesis in an already steatotic liver (46, 47). Therefore, an overabundance of 
dietary fats in combination with increased lipolysis and elevated de novo 
lipogenesis are believed to eventually promote hepatic inflammation, leading to a 
downward spiral of metabolic disruptions. 
2.6.2 Consequences of NAFLD 
 Individuals diagnosed with NAFLD, show elevated NEFAs, serum TAG, 
and serum LDL, regardless of whether they are diabetic or not (9). Also, it has 
been reported that this pro-athrogenic lipid profile observed in NAFLD is 
attributed primarily to insulin resistance (71). Mice with liver specific insulin 
receptor knockouts (LIKO) have been studied to better understand the 
deleterious effects of NAFLD-induced hepatic insulin resistance. Despite being 
on a standard chow diet, these mice reportedly have low levels of HDL. 
Moreover, VLDLs of these mice contained high levels of cholesterol rather than 
triglycerides. Within 12 weeks under these pro-athrogenic conditions, all LIKO 
mice developed severe atherosclerosis (71). From this it is clear that the 
detrimental effects of NAFLD stem far beyond the boundaries of the liver and 
elicit numerous systemic consequences.  
Aside from the impairments in lipid metabolism, glucose metabolism has 
also been reported to be dysfunctional at the intra-hepatic and systemic levels. 
During a hyperinsulinemic-euglycemic clamp, Bugianesi et al., found that 
compared to normal subjects, those who were non-diabetic but had NAFLD 
elicited 30-45% less peripheral glucose disposal despite having normal HGP. 
 35 
This was mainly attributed to impaired whole-body glycogen synthesis and 
glucose oxidation in these individuals. Furthermore, NAFLD subjects had 
significantly higher rates of lipid oxidation which was suppressed to a lesser 
extent in the presence of insulin when compared to controls(9). In a separate 
study, Marchessini et al., investigated insulin’s ability to suppress HGP using the 
same clamp model. They found that the level of impairment in HGP suppression 
in NAFLD patients was similar to that of T2D. They also reported significantly 
less suppression of HGP compared to controls (8). This finding supports the 
notion that insulin resistance is a significant contributor to metabolic 
abnormalities resulting from NAFLD. 
Finally, in its most pronounced stages, NAFLD has been shown to be 
associated with hepatocellular carcinoma and even liver failure (11). Moreover, 
serum aspartate transaminase (AST) and alanine transaminase (ALT), two 
markers of liver damage are significantly elevated in NAFLD patients (9).  
2.7 Exercise 
 
 Healthcare professionals are prescribing exercise as a therapeutic tool to 
aid in the management of numerous metabolic conditions including obesity, T2D 
and NAFLD. Moreover, given that there are currently no approved therapies for 
NAFLD, exercise is one of two options available for its management. Studies 
have repeatedly shown improvements in glucose tolerance, insulin sensitivity, 
and blood lipid profiles in those who are physically active compared to sedentary 
individuals (13)(72). In fact it has been reported that in T2D patients there is 
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improved post-prandial glycemic control after as little as 7 days of aerobic 
exercise training (73). 
 Aerobic exercise is preferred over resistance training for improvement in 
metabolic efficiency. However one randomized control study comparing the 
effectiveness of aerobic vs. resistance training in NAFLD patients showed similar 
improvements in insulin sensitivity, hepatic fat content, and reversal of hepatic 
steatosis. Additionally, total body fat mass, visceral adiposity, and HbA1C (a 
marker of elevated blood glucose over last 3 months) levels were reduced in 
similar magnitudes between both aerobic and resistance-trained subjects (13).  
 Considering the implications that HF feeding has on NAFLD, the effects of 
exercise in conjunction with HF feeding has gained a lot of attention in recent 
years. HF feeding alone has been shown to induce a 2.2-fold increase in total 
hepatic lipid content. Interestingly, exercise was able to reverse the accumulation 
of intra-hepatic lipids by ~ 36%. Cintra et al, claim that the benefits in hepatic lipid 
content mobilization were associated with reduced SREBP-1c and FAS protein 
content (12). Moreover, these findings are further supported by Rabøl et al. who 
show that a single bout of exercise reduced de novo lipid synthesis by 30% and 
hepatic triglyceride synthesis by 40% (74).  
The down regulation in SREBP-1c and FAS are likely due to improved 
insulin sensitivity. Insulin tolerance tests have reported that exercise improves 
glucose clearance from the blood by 41% in rats with diet-induced obesity (40).  
Current literature focuses heavily on the acute (single bout) effects of 
exercise and/or HFD on glycemic control. These models give us some insight 
into the mechanisms of glycemic control and how they may be modified based on 
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acute lifestyle changes. However, they fail to portray the physiological adaptions 
seen from long-term adherence to exercise. Moreover, exercise is currently 
understood to be a long-term lifestyle intervention. Accordingly, our model of 
chronic HFD in conjunction with chronic exercise illustrates the benefits of a life-
long adherence to training. Given that the last exercise bout is 48-hr prior to 
sacrifice, any changes we observe are due to actual metabolic alterations and 
not simply due to an acute exercise-induced stimulus.  
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3. Objectives and Hypotheses 
 
In this context, the objectives of this thesis are twofold: 
1) To determine whether endurance training reverses the deleterious 
metabolic effects of NAFLD by improving insulin signaling, increasing 
glycogen synthesis, and suppressing GNG in the liver 
 2) To investigate the potential molecular mechanisms by which endurance 
exercise improves hepatic glucose metabolism under basal and insulin-
stimulated conditions.  
The hypotheses to be tested are:  
• That endurance exercise will increase fat oxidation, attenuate hepatic 
steatosis and improve whole-body glycemic control in HF-fed rats. 
• That the HF-induced increase in PGC-1α and PEPCK in the liver will be 
reversed by endurance exercise. 
• That endurance exercise will prevent the HF diet-induced impairment in 
insulin signaling in the liver and increase glycogen synthesis while 
suppressing GNG. 
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4. Experimental Design & Methods 
 
4.1 Animals 
All experimental procedures were subject to approval by the York 
University Animal Care Ethics Committee prior to beginning the study. Male 
albino rats from the wistar strain weighing ~200 g (initial weight) were maintained 
on a 12 h light (7:00-19:00) and 12 h dark (19:00-7:00) cycle and left to 
acclimatize for one week at 23° C. Upon acclimatization the rats were screened 
on three separate occasions for their willingness to exercise using an exercise 
selection protocol. This protocol began with a 5 min warm up period consisting of 
an inclination and speed of 5% and 10m/min respectively. After the warm up, 
treadmill inclination was raised to 10% for the remainder of the protocol and 
speed was increased by 2 m/min up to a maximum of 30m/min. Rats that were 
unable to run at a minimum speed of 20 m/min for 20 min on all 3 occasions were 
used as controls. Subsequent to the selection process, rats were randomly 
divided into 4 groups (n=8): sedentary standard chow (Sed SC), exercise 
standard chow (Ex SC), sedentary high-fat (Sed HF), and exercise high-fat (Ex 
HF). The animals’ ad libitum food intake and body weight was measured on a 
daily basis. Both the SC and HF foods were obtained from Research Diets. The 
SC diet contained 70%, 10%, and 20% of the calories from carbohydrates, fat, 
and protein respectively. The HF diet contained 20.1%, 59.9%, and 20% of the 
calories from carbohydrates, fat and protein respectively.  
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4.2 Exercise Training Protocol  
In order to set the training intensity, animals in the Ex SC and Ex HF 
groups underwent a peak VO2 test using a treadmill connected to the 
Comprehensive Laboratory Animal Monitoring System (CLAMS). Once resting 
VO2 was recorded, the 5-min-warm-up-period began (10 m/min, 0% inclination). 
The speed of the treadmill was then increased by 2m/min every two minutes 
thereafter. The test ended when the rats reached exhaustion (characterized by 
sitting on the shock pad for 5 seconds, plateau in VO2, or RER of 1 or higher). 
Using the peak VO2 values, a protocol was designed to have the animals 
undergo chronic endurance training for 1 h/day, 5 days/week up to a maximum 
speed that corresponds to 70-85% of their peak VO2. This was chosen due to the 
fact that it is the same intensity recommended by the American College of Sports 
Medicine (ACSM) for optimal health benefits in humans(75). Furthermore, VO2 
assessments were conducted bi-weekly so running intensity could be adjusted to 
remain constant (70-85% of peak VO2) as the animals improved their running 
capacity with training. In order to maintain conditions across all four groups, 
sedentary animals were also placed on treadmills for 1 h/day. The speed of 
treadmill was constant and set at 2 m/min with no inclination. 
 
 
 
 
 
 41 
4.3 Determination of Glycogen Synthesis/Content  
After 8 weeks of diet and exercise interventions, the animals were 
anesthetized (Ketamine/Xylazine (0.4 mg and 8 mg/100g body weight, 
respectively) and liver samples were taken. Liver slices weighing ~ 18-20 mg 
(weight proven to have optimal perfusion based on previous studies in our 
laboratory) were taken. These slices were incubated at 37°C in Krebs Ringer 
buffer (KRB) containing BSA (4%), 5.5 mM glucose, and 0.2 µCi/ml D-14C-
glucose under either basal or insulin-stimulated (100nM) conditions. The tubes 
were continuously gasified (95% O2:5% CO2) during the for 1 hour. Upon 
completion of the incubation process, samples were snap frozen in liquid N2 and 
then digested in 500 µl of KOH (1M) at 90°C for 30min. Of the digested sample, 
100 µl was taken for analysis of glycogen content while the remaining 400 µl was 
used to assess glycogen synthesis.  
 For glycogen synthesis, 100 µl of carrier glycogen, 80 µl of Na2SO4, and 
1.2 ml of cold ethanol were added to the digested solution and left to precipitate 
overnight. The samples were then centrifuged for 10 min at 13,000 rpm and the 
supernatant discarded. The remaining pellet was dissolved in 0.5 ml of water and 
added to 5 ml of scintillation fluid and left to count in the scintillation counter.  
 Glycogen content measurements were carried out using 100 µl of KOH 
digested sample. 10% (v/v) of acetic acid 17M, 500 µl of acetate buffer (4.8 pH) 
with amyloglucosidase (0.5 mg/ml) were added and the resulting solution was left 
to incubate overnight. On the following day, the solution was neutralized with 
1/16 (v/v) of NaOH (5N). Subsequently, 1 ml of ATP-TRA buffer was added to 
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each sample and then vortexed. Lastly, 1 ml of the solution was placed in a 
cuvette and counted on the spectrophotometer at 340 nm.  
4.4 Insulin Signalling 
Slices of liver weighing ~ 18-20 mg were taken and incubated at 37°C for 
30 min in KRB containing BSA (4%) and 5.5 mM D-glucose either under basal or 
insulin-stimulated conditions. The tubes were continuously gasified (95% O2:5% 
CO2) during the incubation period. Following incubation, the samples were then 
immediately snap frozen in liquid N2 and stored in -80°C. Insulin signaling was 
studied using western blotting protocols in which the frozen samples are 
homogenized in buffer containing 135 mM NaCl, 1 mM MgCl2, 2.7 mM KCl, 20 
mM Tris, 1% Triton X-100, 10% Glycerol, protease inhibitor (1:100) (cOmplete 
ULTRA Tablets), and phosphatase inhibitor (1:100) (PhosStop) (Roche 
Diagnostics GmbH, Mannheim). Protein concentration was measured using the 
Bradford method. Finally the samples were diluted 1:1 in lammeli buffer, heated 
at 95°C for 5min, and subjected to SDS-PAGE. Samples were run against 
antibodies for PEPCK, PGC-1α, Total AKT, P-AKT (Ser473), Total GSK3α, P-
GSK3α, GYS, P-GYS, FAS and β-Actin (loading control). PEPCK antibody was 
obtained from Abcam (Cambridge, MA). The remaining antibodies were from Cell 
Signalling Technology Inc (Beverly, MA). 
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4.5 Determination of Palmitate Oxidation 
In order to measure the rate of palmitate oxidation, slices of liver weighing 
18-20 g were incubated in KRB at 37°C containing [1-14C] Palmitic acid from GE 
Healthcare Radiochemicals (Quebec City, QC). One hour later, an eppendorf 
containing a piece of filter paper covered with 200µl (1:1, vol/vol) 2-
phenylethylamine/methanol was added to the vial and the vial was incubated for 
another hour.  At the end of the second hour, 200 µl of sulfuric acid (5N) was 
added to the incubation medium. Finally, after one-hour incubation, the filter 
paper was removed, and placed in a scintillation vial for radioactivity counting in 
10 ml of scintillation fluid. 
4.6 Intraperitoneal Glucose Tolerance Test (IPGTT) 
A glucose tolerance test was conducted before and after the diet/exercise 
interventions. The animals were fasted overnight prior to initiating the procedure. 
On the day of the test, baseline (Time 0) blood glucose readings were taken from 
the saphenous vein. Subsequently, rats were injected intraperitoneally (i.p.) with 
a 20% glucose solution (2 g/kg prepared in physiological saline) and blood 
samples were taken at 15, 30, 60, and 120 min post injection. Once the test was 
completed, the rats returned to their regular ad libitum diet patterns.  
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4.7 Intraperitoneal Pyruvate Tolerance Test (IPPTT) 
After a 14-hr fast, basal blood glucose was measured from the saphenous 
vein. Subsequently, a 25% sodium pyruvate solution (2.0 g/kg dissolved in water, 
pH 7.4) was administered and blood glucose readings were taken at 15, 30, 60, 
90, and 120 min post injection. Once the test was completed, the rats returned to 
their regular ad libitum diet patterns. 
4.8 Glucose 6-Phopshate (G6P) Quantification 
~ 50 mg of liver was homogenized in 150 µl of ice-cold PBS. Samples 
were centrifuged for 10min @ 12,000rpm (4°C) and the supernatant was 
extracted. Subsequently, the supernatant was spun down using a 10kDa 
molecular weight cut off spin column to remove any enzymes, which may 
interfere with the assay. Hepatic G6P was measured through a calorimetric 
assay using a commercially available kit (Abcam, Cat # ab83426). 
4.9 Triglyceride Quantification 
 ~ 100 mg of liver was heated in 1 ml of 5% NP40 at 90°C for 10min. 
Samples were homogenized and heated once again at 90°C for 5min. 
Subsequently, samples were allowed to cool down to room temperature after 
which they were heated once again for 5min at 90°C. Lastly, they were 
centrifuged to remove insoluble components and assayed using a commercially 
available calorimetric kit (Abcam, Cat# ab65336). 
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4.10 Circulating Insulin  
 After a 14-hr fast, blood samples were collected from the saphenous vein 
at week 0, 3, & 6 for analysis of circulating insulin concentrations. Samples were 
immediately centrifuged @ 13,000 rpm for 10 min (4°C). Plasma was extracted 
and stored at - 80°C. Plasma was assayed using a commercially available ELISA 
from EMD Millipore (Cat # EZRMI-13K). 
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5. Results  
5.1 Qualitative Analysis of Hepatic Lipid Accumulation 
Qualitative observations of liver samples show successful induction of 
NAFLD through the diet-induced obesity model. The Sed HF liver (Figure 5B) 
had severe discolouration compared to controls (Figure 5A). Moreover, a dotted-
appearance throughout the HF liver indicates an accumulation of lipid droplets. 
Exercise attenuated hepatic lipid accumulation in rats on the same HFD (Figure 
5C) and presented an appearance that is more similar to the control liver.  
 
     a)  Sed SC        b)   Sed HF   c) Ex HF 
 
 
Figure 5. Liver from rats after 8 weeks of chronic diet and/or exercise 
interventions. A) Sed SC showed excellent perfusion with no signs of lipid 
accumulation. B) Sed HF had significant lipid accumulation and discolouration. C) 
Exercise elicits significant improvement in liver appearance even on HFD. 
Samples were washed in ice-cold PBS. 
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5.2 Quantitative Analysis of Hepatic Triglyceride Content 
 
 Knowing that HFD clearly induced NAFLD, we wanted further to quantify 
the extent of this hepatic lipid accumulation. We therefore measured hepatic TAG 
content and as expected, rats on a HFD had significantly higher hepatic lipid 
accumulation compared to Sed SC. In fact, TAG content was 10.5-fold higher in 
the Sed HF rats compared to Sed SC. Moreover, Ex HF showed a 24% reduction 
in hepatic triglyceride content compared to Sed HF animals. 
 
Figure 6. Hepatic triglyceride content. Chronic HF-feeding results in hepatic 
triglyceride accumulation that is attenuated through exercise. *P<0.05 vs. all 
other conditions; #P<0.05 vs. Sed HF. Data are expressed as mean ± SEM, n=5. 
Two-way ANOVA. 
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5.2 Effects of HFD and Exercise on Circulating Insulin 
 Circulating insulin was measured throughout the study from blood samples 
taken at week 0, 3, and 6. Insulin values were similar across all groups at 
baseline. At week 3, Sed HF rats displayed significantly higher insulin levels, 
which was heightened further at week 6. Interestingly, exercise reverses insulin 
resistance even in animals that are fed a HFD.  
 
Figure 7 – Indices of whole body insulin-resistance. Blood samples were taken 
from overnight fasted rats to quantify circulating insulin concentrations in Sed SC, 
Ex SC, Sed HF, & Ex HF rats. *P<0.05 vs. Sed SC; #P<0.05 vs. Sed HF. Data 
are expressed as mean ± SEM, n=6. Two-way ANOVA. 
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5.3 Effects of HFD and Exercise on Whole-Body Glycemic Regulation 
 In order to examine the effects of HF-feeding and endurance exercise on 
glucose tolerance we performed an IPGTT (Figure 8A). Sed HF rats displayed 
significantly higher blood glucose than Sed SC across all time points, including 
under basal conditions. In fact, the area under the curve (AUC) for glycemia was 
1.27-fold higher in Sed HF than Sed SC rats (Figure 8B). Exercise markedly 
improved blood glucose clearance in both SC- and HF-fed rats by 20% and 13%, 
respectively. In fact, chronic endurance exercise completely reversed the whole-
body insulin resistance found in Sed HF rats. This is supported by the fact that 
the AUC for glycemia did not differ between Ex HF and Sed SC rats (Figure 8B).  
 
Figure 8. Indices of whole-body Glycemic Control following 8 weeks of HFD   
and Endurance Training A) IPGTT performed after overnight fasting in Sed SC, 
Ex SC, Sed HF, Ex HF rats. B) Area under the curve (AUC) corresponding to 
IPGTT. *P<0.05 vs. Sed SC; #P<0.05 vs. Sed HF. Data are expressed as mean ± 
SEM, n=18. Two-way ANOVA.  
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5.4 Pyruvate Tolerance Test 
 Knowing that HFDs are associated with elevated plasma glucose and 
impaired glucose clearance, we wanted to understand whether this outcome of 
insulin resistance could be attributed particularly to the liver. As a result, we 
performed a pyruvate tolerance test to identify liver-specific insulin resistance and 
uncontrolled glucose production. Preliminary studies analyzing the effects of HFD 
on pyruvate tolerance show significantly higher blood glucose concentrations at 
30, 60, 90, and 120min post injection (Figure 9A). Moreover, HFD elicits 
significantly higher glucose production with significance using area under the 
curve (1137.4 vs. 1496.6 Arbitrary Units)  (Figure 9B).  
 
 
Figure 9. Indices of liver-specific insulin resistance and pyruvate intolerance 
following 8 weeks of HFD. A) IPPTT performed after overnight fasting in Sed SC 
and Sed HF rats. B) Area under the curve (AUC) corresponding to IPPTT. 
*P<0.05 vs. Sed SC. Data are expressed as mean ± SEM, n=10. Independent t-
Test. 
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5.5 Glycogen Synthesis 
 Given the elevated hepatic glucose production, and whole body as well as 
liver-specific insulin resistance seen following chronic HFD, it was imperative to 
understand how hepatic glycogen synthesis operates under these conditions. We 
therefore incubated slices of liver under basal and insulin-stimulated conditions 
and quantified the rate of glycogen synthesis. Exercise reduced the rate of 
glycogen synthesis in both basal and insulin stimulated livers. The exercise-
induced differences in glycogen synthesis were only significant in HF animals 
under basal conditions, although SC exercisers still saw ~ 20% reduction (Figure 
10A). Furthermore, upon insulin stimulation, both SC and HF exercisers saw 
significant reduction in the rate of glycogen synthesis (Figure 10B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 52 
 
Figure 10. Effects of SC- or HF-feeding and exercise on rates of glycogen 
synthesis. A) Comparing Sed SC, Ex SC, Sed HF, & Ex HF under basal 
conditions. B) Comparing Sed SC, Ex SC, Sed HF, & Ex HF under insulin 
stimulated (100 nM) conditions. Slices of liver were incubated for 1 hour in KRB 
buffer in the presence or absence of insulin (100nM) and radiolabelled D-14C-
glucose. All values are expressed as nmol/mg of wet tissue. *P<0.05 vs. all other 
conditions. $P<0.05 vs. Sed SC. #P<0.05 vs. Sed HF. Data are expressed as 
mean ± SEM, n=6. Two-way ANOVA. 
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5.6 Glycogen Content 
 Knowing that exercise reduced the conversion of glucose to glycogen, we 
wanted to know whether this reduction translated into a reduction in overall 
glycogen content. As a result we used a sample from the same incubated liver 
slices used in the glycogen synthesis assay to quantify glycogen content. We 
found no effect of insulin stimulation on absolute glycogen content levels. 
Moreover, there were no differences with diet or training.  
 
 
Figure 11. Effects of diet and exercise on glycogen content in Sed SC, Ex SC, 
Sed HF, and Ex HF rats under basal and insulin-stimulated conditions. Slices of 
liver were incubated for 1 hour in KRB buffer either in the absence or presence of 
insulin (100 nM). All values are expressed as µmol of glucosyl units/mg of wet 
tissue. Data are expressed as mean ± SEM, n=9. Two-way ANOVA. 
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5.7 Glucose 6-Phosphate 
 In order to better understand the mechanism behind reduced rates of 
glycogen synthesis in exercised animals, we measured intracellular G6P. We 
assessed G6P hypothesizing that exercised animals may have reduced G6P 
resulting in a blunted allosteric activation of GYS. Contrary to our expectations, a 
mild increase was seen in exercised animals although these observations were 
not found to be significantly different.  
 
Figure 12. Measurement of G6P using calorimetric assay. Comparing Sed SC, 
Ex SC, Sed HF, and Ex HF liver homogenates under basal conditions. No 
Significant differences were found between groups. Data are expressed as mean 
± SEM, n=6. Two-way ANOVA. 
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5.8 Effects of HFD and Exercise on Insulin Signalling for Glycogen 
Synthesis 
We performed western blot analysis in order to determine the effects of 
HFD and exercise on intracellular proteins involved in the insulin-signaling 
cascade for glycogen synthesis. Samples were run against antibodies for 
phosphorylated forms of AKT, GSK3, and GYS.  AKT phosphorylation was 
significantly greater at Ser473 with chronic exercise under both diets (Figure 13A). 
GSK3α, the downstream protein from AKT saw increased phosphorylation of its α 
isoform at Ser21 with exercise, although this difference was only found to be 
significant in the Ex SC group (Figure 13B). Finally, despite increased 
phosphorylation of AKT and GSK3α in exercised animals, GYS, which is 
negatively regulated by phosphorylation remained phosphorylated at Ser641 with 
exercise; a result that was significant in Ex HF animals (Figure 13C). 
Nevertheless, western blots for phosphorylation of GYS support earlier data 
depicting reduced rates of glycogen synthesis in exercised rats.  
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A)         B) 
    
 
 
 
C)  
 
 
Figure 13. Representative blots and densitometric analysis of proteins in the 
insulin-signaling cascade for glycogen synthesis. Effects of diet and exercise on 
phosphorylation of a) AKT (n=5), b) GSK3α (n=6), and c) GYS (n=5) in frozen 
liver homogenates. Samples were prepared for SDS-Page as described in 
methods. *P<0.05 vs. Sed SC. #P<0.05 vs. Sed HF. Data are expressed as mean 
± SEM.  Two-way ANOVA.   
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5.9 Effect of HFD & Exercise on Proteins involved in Gluconeogenesis 
 Having witnessed the elevated GNG in response to HFD through the 
pyruvate tolerance test, we subsequently performed western blots for proteins 
involved in the GNG pathway. HFD significantly increased cytosolic PEPCK 
(Figure 14A). However, when fed a HFD in conjunction with exercise, these HF-
induced elevations in PEPCK were significantly reduced. The reduction in 
PEPCK with exercise is accompanied by paralleled reductions in PGC-1α (Figure 
14B). 
 
A)        B) 
    
 
Figure 14. Representative blots and densitometric analysis of gluconeogenic 
proteins. Western Blots were performed for a) PEPCK (n=5) and b) PGC-1α 
(n=4) in frozen liver homogenates. Samples were prepared for SDS-Page as 
described in methods. *P<0.05 vs. Sed SC. #P<0.05 versus Sed HF. Data are 
expressed as mean ± SEM. Two-way ANOVA. 
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5.10 Effects of HFD & Exercise on de novo Lipogenesis 
 Additional western blots were performed for FAS, the terminal protein in 
de novo lipid synthesis. HFD results in significantly lower FAS content. Moreover, 
exercise had no effect on the content of this protein.  
 
 
 
Figure 15. Representative blots and densitometric analysis of FAS. Western Blots 
were performed for FAS in frozen liver homogenates. Samples were prepared for 
SDS-Page as described in methods. *P<0.05 vs. Sed SC. Data are expressed as 
mean ± SEM, n=5. Two-way ANOVA. 
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5.11 Palmitate Oxidation 
We measured palmitate oxidation to understand how HFD and exercise 
affects rates of FAO in the liver. As expected, HFD increased hepatic FAO 
although this was not found to be significant.  Given that qualitative observations 
indicated a reversal of NAFLD, we expected to see higher rates of palmitate 
oxidation upon exercise. In contrast to our expectations, exercise reduced 
oxidation; a result that was found to be significant in the Ex HF group.  
 
 
Figure 16. Measures of palmitate oxidation under basal conditions Liver slices 
were incubated in [1-14C] Palmitic acid at 37°C. One hour later, an eppendorf 
containing a piece of filter paper covered with phenetylamine (200 µl of a 1:1 
dilution in methanol) was added to the vial and the vial was incubated for another 
hour.  At the end of the second hour, 200 µl of sulfuric acid (5N) was added to 
the incubation medium. Finally, after one-hour incubation, the filter paper was 
removed, and placed in a scintillation vial for radioactivity counting in 10 ml of 
scintillation fluid. #P<0.05 versus Sed HF. Data are expressed as mean ± SEM, 
n=5. Two-way ANOVA.  
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5.12 Effect of HFD & Exercise on Subcutaneous WAT Cell Lipolysis 
 In order to test the contribution of lipolysis to NAFLD, we measured free 
glycerol in subcutaneous WAT cells. HFD elevated lipolysis significantly when 
compared to standard chow controls. Moreover, feeding a HFD with chronic 
endurance training significantly reduces lipolysis by ~ 57% compared to the Sed 
HF group. These results are in line with the qualitative observations of hepatic fat 
content in addition to hepatic triglyceride results alluded to in Figure 1 and 2 
respectively.  
 
Figure 17. Measures of WAT cell lipolysis under basal conditions. WAT cells were 
isolated and lipolysis was measured in Sed SC, Ex SC, Sed HF, and Ex HF rats .  
*P<0.05 versus Sed SC. #P<0.05 versus Sed HF. Data are expressed as mean ± 
SEM, n=6. Two-way ANOVA.  
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6. Discussion 
 
Here we report that chronic endurance training exerts an anti-steatotic 
effect and improves insulin signaling in the liver of HF-fed rats. This is shown 
through visual observations (Figure 5B) in which we spotted severe 
discolouration in liver from HF-fed rats. Moreover, a dotted appearance 
throughout the course of the liver indicates excessive hepatic lipid accumulation. 
In line with these observations, we have evidence to show HFD induces a 10.5-
fold greater hepatic triglyceride content compared to those fed a SC diet (Figure 
6). Importantly, exercise reduced the hepatic TG content by 24%. These 
observations are indicative of a successful induction of NAFLD using our diet-
induced obesity model and that exercise can significantly reduce HFD-induced 
hepatic lipid accumulation. 
 It has been reported that the body is able to preferentially shift substrate 
metabolism to the most abundant and readily available substrate (42). As such, it 
would be expected that under conditions of HF-feeding, the system would 
preferentially oxidize fats in an attempt to remove them and prevent ectopic lipid 
accumulation. Such is the case in the rats of this study, as HF-feeding has shown 
to increase the rate of palmitate oxidation by 1.48-fold compared to SC rats 
(Figure 16). However, this compensatory mechanism seems to be overpowered 
by the abundance of incoming dietary lipids, as well as by the enhanced supply 
of NEFAs through increased white adipose tissue lipolysis. Consequently, ectopic 
fat accumulation continues to take place despite having elevated lipid oxidation in 
the liver. These results are consistent with findings by Bugianesi et al, who found 
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that increased hepatic lipid infiltration was accompanied by elevated lipid 
oxidation in non-diabetic NAFLD patients (9).  
Numerous studies have supported the notion that NAFLD is in part 
induced through increased de novo lipogenesis (10, 76). We provide evidence to 
suggest otherwise. Under resting conditions, western blot analysis revealed that 
FAS, the terminal enzyme of de novo lipid synthesis, was significantly reduced 
with HF-feeding (Figure 15). As a result, de novo lipogenesis is expected to be 
reduced. This anabolic process is normally activated under conditions of elevated 
insulin and low glucagon levels. However, in HF steatotic animals, insulin 
signaling is impaired (77), which should cause a decline intracellular malonyl-
CoA levels. As a result, there would be an increase in CPT1 activity and FAO, 
while simultaneously reducing de novo lipid synthesis. Shimomura et al., found 
that despite a reduction in IRS2 content and phosphorylation of AKT, SREBP-1c 
mRNA increased as a consequence of obesity-induced hyperinsulinemia. 
Accordingly, they suggest that there must be an alternate pathway independent 
of IRS2 to elicit these insulin-mediated effects (78). However, due to post-
translational modifications, the presence of mRNA doesn’t always guarantee the 
presence or activity of protein. We were able to show FAS protein content, which 
is normally elevated in an SREBP-1c induced manner, is in fact reduced with 
HFD.  
Lastly, enhanced lipolysis is believed to be a major source of NEFA 
delivery to the liver in an insulin resistant state (Figure 7). Measurement of 
lipolysis in subcutaneous WAT cells revealed significantly higher (1.77-fold) 
levels of free glycerol (a marker of lipolysis) following high fat feeding (Figure 17). 
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Chronic endurance training reduced basal lipolysis by ~ 57% in the 
subcutaneous inguinal fat, an effect that likely resulted from exercise-induced 
improvement in insulin sensitivity.  We therefore conclude that the majority of lipid 
abundance seen in NAFLD patients is due to excessive fat intake through the 
diet and increased lipolysis resulting from insulin resistance, but not due to 
elevated de novo lipogenesis.   
Interestingly, despite the clearance of lipids from the liver following chronic 
exercise, hepatic lipid oxidation is reduced in all exercised rats (Figure 16). This 
reduction was found to be significant in Ex HF animals compared to the Sed HF 
group. Despite the preferential shift to fat oxidation under basal conditions in a 
trained state (79, 80), hepatic lipid oxidation itself seems to react differently. 
Considering fatty acid oxidation occurs in the mitochondria, and PGC-1α 
regulates mitochondrial biogenesis, the significant reduction in PGC-1α content  
(Figure 14B) following training may explain the reduced intrahepatic fat oxidation. 
These results suggest that although hepatic lipid content is reduced with 
exercise, these lipids are not being heavily oxidized in the liver, but rather in 
peripheral tissues such as skeletal muscle which have their metabolic activity 
highly increased during chronic exercise (81).  
  It has been well established in the literature that NAFLD is closely 
associated with T2D, and thus impaired glucose regulation. We therefore shifted 
our attention to how the system goes about maintaining glycemic control under 
these conditions. Clearly high fat diet induces severe hyperinsulinemia which 
progressively worsens with chronic HFD (Figure 7). Results from an IPGTT 
(Figure 8) are in agreement with previous studies which show significant glucose 
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intolerance and insulin resistance following HFD (82, 83). In fact, these rats 
display significantly higher blood glucose readings across all time points including 
basal glucose readings compared to Sed SC (control). This may be attributed to 
the disruption of a number of glucose homeostatic mechanisms including GNG, 
glycogen synthesis, glycolysis, and glycogenolysis. Moreover, an IPGTT 
assesses whole body glucose intolerance and IR; therefore, the resulting 
hyperglycemia may also be attributable to metabolic disruptions that HF-feeding 
caused in peripheral tissues such as skeletal muscle or adipose tissue.  Although 
the exact mechanism behind this insulin resistance is unclear, we provide 
evidence that hepatic lipid accumulation is the culprit behind this impairment. Our 
reasoning for this lies behind the fact that following 8 weeks of chronic exercise, 
NAFLD is significantly reduced (Figure 5C & Figure 6) and glucose tolerance was 
improved in exercised animals fed either standard chow or a HFD (Figure 8B). 
These data suggest that exercise is an effective therapeutic tool in reducing 
whole-body glucose intolerance and insulin resistance.  
 In both diabetes and obesity-induced insulin resistance, hepatic glucose 
production is a significant contributor to both the elevated fasting hyperglycemia 
and uncontrolled postprandial hyperglycemia. Although numerous IPGTT 
measures in our lab were indicative of whole body insulin resistance, we wanted 
to be able to demonstrate that this whole body glucose intolerance was in part 
attributable to hepatic insulin resistance. We therefore conducted an IPPTT in our 
preliminary studies involving control and HF rats to establish this. As shown in 
Figure 9A, the HF animals convert a larger proportion of the injected pyruvate 
into glucose and releases it into circulation. As a result, they display significantly 
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higher plasma glucose levels (Figure 9B). A higher rate of conversion of GNG 
precursors to glucose is indicative of insulin resistance and thus overactive GNG. 
Therefore, in patients with NAFLD, elevated GNG is one of the culprits 
contributing to elevated fasting and postprandial hyperglycemia in diabetes and 
NAFLD.  
 To further investigate the mechanisms behind elevated de novo glucose 
production, we performed western blot analysis of key proteins involved in the 
GNG pathway. As expected, HF-feeding resulted in significantly higher PEPCK 
content, which would promote the GNG pathway illustrated through the IPPTT. 
Interestingly, and in agreement with current literature, both PEPCK and PGC-1α 
parallel one another in their expression patterns (31, 33). That is, with chronic 
exercise (a more insulin sensitive system), both PGC-1α and PEPCK content are 
reduced (Figure 14). Given that PGC-1α is a transcriptional co-activator of GNG 
genes, these results suggest that reduced PGC-1α results in less transcription of 
PEPCK. The result is reduced de novo glucose production and improved blood 
glucose profiles in exercised animals. Moreover, the activity of PGC-1α depends 
highly on transcription factor availability (28, 33). Normally, FOXO1 is excluded 
from the nucleus through AKT mediated phosphorylation, thereby preventing 
PGC-1α-FOXO1 interaction and gene transcription (40). Once again, with 
exercise, we demonstrate improved insulin sensitivity through increased AKT 
phosphorylation in both standard chow and HF fed rats (Figure 13A). As a result, 
this would promote FOXO1 phosphorylation and exclusion from the nucleus, 
thereby reducing GNG gene transcription. These results are consistent with 
findings from Ropelle et al. who observed similar AKT mediated reduction in 
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PGC-1α and a concomitant reduction in GNG genes in rats subjected to two 3h 
acute exercise bouts (40). From this it is clear that the exercise-induced reduction 
in GNG is not only present after acute exercise, but also during resting conditions 
following chronic endurance training.  
 Although we have shown that hyperglycemia in NAFLD is in part due to 
elevated GNG, one cannot ignore the contribution of glycogen synthesis. Aside 
from glycolysis, glycogen synthesis is a significant contributor to the clearance of 
circulating glucose. Here we provide novel evidence to suggest that following 
chronic endurance training, rates of hepatic glycogen synthesis are not 
increased, but rather reduced in basal and insulin-stimulated liver slices (Figure 
10). This presents a paradoxical finding that led us to ask the following question: 
how can hepatic glycogen synthesis be blunted in exercised animals when a 
number of metabolic factors support a more insulin sensitive system with 
exercise? Despite improved AKT and GSK3α signaling, hepatic glycogen 
synthesis was reduced with exercise (Figure 13). However, this impairment of 
glycogen synthesis is clearly not due to an insulin resistant state. The reduction 
in glycogen synthesis is further supported by increased phosphorylation of GYS 
in exercised animals. To further investigate this seemingly counterintuitive 
mechanism, we measured hepatic G6P (Figure 12) to gain insight into whether 
there was less allosteric activation of GYS with exercise. No significant 
differences were found with exercise. In fact a mild increase in G6P was found in 
trained animals, which would theoretically promote allosteric activation of GYS in 
contrast to our observations. Nevertheless, there is a sufficient amount of G6P 
available to allosterically activate glycogen synthesis. Therefore, there must be 
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some alternate metabolic fate of glucose or increasing energy demands in 
peripheral tissues, which force the liver to export glucose rather than storing it.   
 Having identified blunted glycogen synthesis in both basal and insulin 
stimulated conditions, we then measured glycogen content (Figure 11) from the 
same liver slices used to measure glycogen synthesis. Although the rate of 
conversion of glucose to glycogen was reduced with exercise, this did not 
compromise total glycogen content. No differences in were found within groups 
with insulin stimulation or between groups with basal or insulin-stimulation.  
 Impaired glycogen synthesis would normally suggest elevated plasma 
glucose and resultant hyperglycemia. Remarkably, this is not the case as we 
clearly demonstrate significant improvements in both glucose tolerance and 
markers of de novo glucose production with exercise. These results suggest an 
alternate metabolic fate of glucose following chronic endurance training. It could 
be that despite having reduced de novo glucose production, hepatic glucose 
output increases (as a result of increased glycogenolysis) in an attempt to meet 
the heightened energy demands in a trained system.  
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7. Conclusion 
 
 Based on our findings it is clear that chronic HF-feeding induces hepatic 
steatosis to an extent that compromise hepatic as well as whole-body glucose 
metabolism. Despite a compensatory increase in the rate of palmitate oxidation, 
the system is unable to clear the excessive fats incoming through both the diet 
and to a smaller extent, ongoing lipolysis. We have shown that exercise can be 
used as a therapeutic approach to treat the metabolic abnormalities of NAFLD to 
an extent that significantly improves insulin sensitivity, glucose tolerance, and de 
novo glucose production.   
 Insulin resistance is clearly reduced with exercise as illustrated by 
measures of circulating insulin and a smaller IPGTT AUC in both standard chow 
and high fed rats. Moreover, phosphorylation of key proteins involved in insulin 
signaling, namely AKT(Ser473) and GSK3α are enhanced with training. When 
studying GNG, both PEPCK and PGC-1α are significantly reduced with training. 
These effects are likely due to improved insulin sensitivity in the absence of 
hepatic lipotoxicity. 
 Here, we present the novel findings of the reduced rate of glycogen 
synthesis following chronic endurance training. To our knowledge, we are the first 
to witness such a response with chronic HF-feeding and exercise even under 
insulin-stimulated conditions. Importantly, these observations were 48h after the 
last bout of endurance training, indicating that any findings are a result of chronic 
rather than acute exercise. As a result, in a trained system the reversal of NAFLD 
seems to be associated with a preferential shift in substrate metabolism that 
enhances whole-body glucose and hepatic lipid clearance.  
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8. Future Directions 
 
 In our study we observed that chronic endurance exercise has the 
capacity to attenuate HFD induced NAFLD. We also detected paralleled 
reductions in whole body glucose intolerance and improvements in insulin 
sensitivity. These observations are seen even in the paradoxical conditions of 
both reduced hepatic palmitate oxidation and glycogen synthesis in rats under 
chronic HF-feeding and endurance training. Accordingly, there are a number of 
follow-up experiments to be conducted that may potentially clarify the mechanism 
behind these findings.  
8.1. Hepatic glucose output 
 Perhaps the reduction in glycogen synthesis is in part due to increased 
hepatic glucose output in a trained system. This may be a valid mechanism 
considering the role of the liver is to export glucose to peripheral tissues based 
on energy demands of the body. Increasing energy demands in trained animals 
would require the liver to release glucose through glycogenolysis into circulation 
rather than storing it as glycogen. These experiments can be carried out by 
incubating liver slices in KRB buffer in the absence of glucose and subsequently 
measuring glucose in the buffer. Moreover, three slices of liver will be taken for 
basal, insulin, and glucagon stimulated measures. Due to the absence of glucose 
in the buffer, glucose present after the incubation period must therefore be a 
result of HGO.  
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8.2. Glucose oxidation 
 Given that hepatic glycogen synthesis is reduced following training, this 
raises the possibility of heightened glucose demand in peripheral tissues. 
Accordingly, measuring both hepatic as well as whole-body glucose oxidation 
may help clarify the fate of glucose in exercised animals.  
8.3 Western Blot analysis of ACC & Regulators of Glycogen Synthase   
  In order to explain the reduction in palmitate oxidation in the liver, it is 
imperative that we measure both total and phosphorylated ACC. Reduced 
phosphorylation of ACC with exercise is expected given that this protein is active 
in its dephosphorylated state. Active ACC results in increased production 
malonyl-CoA, however we have reported in the present study that FAS activity is 
reduced with high fat diet. Accordingly, a build up of malonyl-CoA would in theory 
inhibit fatty acid oxidation (as we have shown). 
 Next, we found no differences with respect to intra-hepatic G6P 
concentrations between any of the groups. Therefore, it is unlikely that the 
inactivation of GYS seen with training is accomplished through allosteric 
regulation. Therefore, we need to focus our attention on known covalent 
modifiers of GYS activity. These include AMPK, PKA, and PP1.    
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10. Appendices  
10.1 Appendix A - Detailed Experimental Methods 
10.1.1 Lysis Buffer for Homogenization 
 
Reagent Concentration/MW 
NaCl 135mmol/L (MW=58.44) 
MgCl2 1mmol/L (MW=203.3) 
KCl 2.7mmol/L (MW=74.55) 
Tris (pH 8) 20mmol/L (MW=121.14) 
Triton 1%  
Glycerol 10%  
 
Prepare lysis buffer stock and store at -20°C. Aliquot desired volumes and add 
protease (cOmplete ULTRA Tablets) and phosphatase (PhoStop) inhibitors 
immediately prior to use.  
 
Laemmli Sample Buffer (2x) - (Bio-Rad, Cat#161-0737) 
Per 1mL: 950µl of 2x Laemmli sample buffer 
            50Ul β-Mercaptoethanol 
Store at room temperature. Dilute the sample (1 in 2) with sample buffer 
and heat for 5min at 95°C. 
 
10.1.2 Preparation of Tissue Lysates 
 
1. Upon extraction, immediately snap freeze samples and store at -80°C. 
2. Weigh sample (~ 20mg for liver) and add to 350µl of lysis buffer containing 
both protease & phosphatase inhibitors. (Always keep samples on ice and 
avoid thawing while weighing tissue) 
3. Thoroughly homogenize the sample. 
4. Centrifuge the tissue lysate for 10min @ 12,000rpm (4°C).  
5. Extract the supernatant and transfer to a fresh micro tube. 
6. Take one aliquot for protein determination by Bradford method.  
7. Aliquot remaining lysate and store at -80°C.   
8. For western blot purposes, dilute lysates with 2x lammeli buffer (1 to 1 v/v) 
as needed and heat for 5 min at 95°C prior to use.  
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10.1.3 Western Blotting Buffers  
 
10x Electrophoresis/Running Buffer (pH - 8.3) 
30.34g Tris base 
144g  Glycine 
10g  SDS 
Dissolve contents in 1L of ddH20 and store at room temperature. 
 
1x Running Buffer (pH- 8.3) 
10%  10x Running buffer 
90%  ddH20 
Mix solutions and store at room temperature. 
 
10x Transfer Buffer (pH- 8.3) 
30.3g  Tris base 
144g   Glycine 
Dissolve contents in 1L of ddH20  and store at room temperature. 
 
1x Transfer Buffer (pH- 8.3) 
10%  10x Transfer buffer 
20%  Methanol 
70%  ddH20  
Mix solutions and store at -20°C prior to use. 
 
10x Wash Buffer  
60.57g  Tris base 
87.66g  Sodium Chloride (NaCl) 
Dissolve contents in 1L of ddH20, store at room temperature. 
 
1x Wash Buffer 
10%   10x Wash buffer 
90%  ddH20  
Add 500Ul/L of Tween-20 and NP-40. Mix solutions and store at room 
temperature. 
 
Blocking Buffer 
3% BSA (w/v: 1.5g/50mL)  
Dissolve in 1x Wash buffer, store at 4°C. 
 
 
Antibody (Ab) Buffer 
1° Ab  – 1 part blocking buffer + 2 parts wash buffer + 0.02% NaAzide (stock in 
ddH20) 
2°Ab – 1 part blocking buffer + 2 parts wash buffer (NO NaAzide).  
Typically 1:1000-1:2000 dilution is appropriate for an Ab. This may vary 
depending on how good the signal is.  
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Resolving gl Tris Buffer (1.5M) (pH-8.8) 
90.86g/500mL of ddH20 
 
Stacking gel Tris Buffer (0.5M) (pH-6.8) 
30.3g/500mL of ddH20 
 
10% APS Solution 
10% (w/v) Ammoniumperoxide Sulfate in ddH20. 
Use 0.1g/mL 
Store at -20°C.  
 
10% SDS Solution 
10% (w/v) Sodium dodecylsulfate in ddH20 
Use 1g/10mL 
Store at room temperature. 
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10.1.4 Western Blotting 
 
1. Take samples out of -80° freezer and place on ice. 
2. Place gels into cassettes, and add the cassette to tank ensuring red and 
black terminals of cassette correspond with red and black markings of tank 
respectively. 
3. Add 1x running buffer to fill the tank. 
4. Once samples have thawed, spin in centrifuge for a few seconds.  
5. Take out combs from gel and pipette 7ul Bio-Rad protein ladder.  
6. Add samples into each well according to Bradford values. 
7. Top up with running buffer to make sure tank is full. 
8. Ensure positive and negative electrodes are matched (black to black, red 
to red) 
9. Turn on the voltage for 60V for 30min, and then turn it up to 110V for        
~1.5hrs until dye runs off the gel. 
10. While gel is running, can prepare 1x transfer buffer. Once transfer buffer is 
well mixed, cover with parafilm and place in the -20°C freezer until ready 
for transfer. 
 
Transferring the Gel onto a membrane 
1. Fill Pyrex dish with cold transfer buffer. 
2. Cut out equal sized membranes and dip in methanol to activate (2min). 
Also cut out equal sized filter papers and prepare the appropriate number 
of foam pads. 
3. Place membranes in transfer buffer after activation. 
4. Once dye has run off the gel, remove the gels from tank and soak in 
transfer buffer. Carefully remove glass plates. Cut off and discard combs 
of the gel. Loosen gel from the glass plate with scraper while keeping it 
emerged in the buffer.  
5. In the pyrex dish, place the black side of the cassette on the bottom, and 
place two foam pads followed by 3 filter papers on top. Ensure there are 
no bubbles. 
6. Carefully place gel on top of filter paper and use the roller to get any air 
bubbles out. Make sure gel is in the correct orientation so that the ladder 
will appear on the left side of the membrane when removed.  
Note: transfer runs from negative (black) to positive (red). Always ensure 
proteins will run from gel to the membrane.  
7. Carefully place the membrane on top of the gel and roll out any bubbles. 
8. Place 3 more filter papers on top and roll out any bubbles.  
9. Add one foam pad and roll out any bubbles.  
10. Carefully close sandwich and place into transfer tank. Make sure black 
matches black and red matches red. 
11. Place ice pack in tank to keep buffer cold. Close the lid ensuring positive 
and negative electrodes are matched (black to black, red to red) 
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11. Surround transfer tank with ice to keep cold.  
12. Turn on transfer at 120V for 2.5 hours or at 60V overnight.  
13. Look for bubbles on ends of cassette to indicate successful transferring. 
14. Check on temperature throughout transfer time to ensure no overheating.   
 
Probing the membrane 
1. Prepare containers to hold blocking buffer for each membrane, approx. 
10mL per container. 
2. Once transfer has finished, open cassettes and quickly place membranes 
in containers with blocking buffer. 
3. Allow the membranes to surf in the blocking buffer for 1hr at room 
temperature on the orbital shaker. 
4. Pour out blocking buffer and add 1°Ab.  
5. Incubate overnight on shaker at 4°C. Ensure containers are fully sealed to 
avoid evaporation. 
6. The next day, remove 1°Ab and wash membranes 5x at 10min intervals 
with 10mL of 1x wash buffer to rid the membrane of any unbound Ab. 
7. Add 2° Ab and allow membranes to surf on orbital shaker for 1hr at room 
temperature.  
8. Remove 2°Ab and wash membranes 5x at 10min intervals with 10mL of 
1x wash buffer to rid the membrane of any unbound 2°Ab. 
9. Membranes are ready for developing 
 
Developing the membrane 
1. For each membrane, use 3mL chemiluminescence (Millipore Immobilon 
Western Chemiluminescent HRP substrate) per membrane and incubate 
for 3 minutes.  
2. Dip membranes into ddH20 to rinse and place in radiography cassette.  
3. In the darkroom, expose film for desired time. 
4. Place film in developer for a few seconds until signal appears. Dip into 
water to stop the reaction, and place in fixer solution. Ensure ample fixing 
time.  
5. Rinse with water and allow drying.   
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10.1.5 Buffers for liver slice incubation  
 
Stock solutions for Krebs Ringer Bicarbonate (KRB) Buffer  
Note: All solutions are made with ddH2O 
 
Quantity Reagent/Molarity 
0.9g in 100ml 0.154M NaCl (mw = 58.44) 
575mg in 50ml 0.154M KCl (mw = 74.55 
610mg in 50ml 0.11 CaCl2  (mw = 110.99) 
1.055g in 50ml 0.154M KH2PO4 (mw = 136.09) 
927mg in 50ml 0.154M MgSO4  (mw = 120.30) 
650mg in 50ml 0.154M NaHCO3  (mw = 84.01) 
 
*Gasify NaHCO3 with carbogen (95% O2/5% CO2) for 1h after assembly. Stock 
solutions can be stored at 0-4°C. 
 
 
KRB Buffer Assembly (for 100ml) 
Note: Adjust volumes accordingly depending on number of samples. 
 
For 100ml of KRB buffer: 
   
 
 
 
 
 
 
 
 
 
 
 
Once assembled, the KRB solution is gasified for 45min with carbogen  
(95% O2/5% CO2). pH the gasified KRB buffer to 7.4 using 10N NaOH. Finally 
add fatty acid free BSA (Sigma Cat# A3803) to the solution at a concentration of 
4% (40mg/ml).  
 
For glycogen synthesis and glycogen content assays, take the required amount 
of KRB Buffer and add radiolabelled D-[14C] glucose at a concentration of 0.2 
µCi/ml.   
 
 
 
 
 
Quantity Reagent/Molarity 
78.6ml 0.154M NaCl 
3.08ml 0.154M KCl 
2.32ml 0.11 CaCl2   
0.768ml 0.154M KH2PO4 
0.768ml 0.154M MgSO4   
16.1ml           0.154M NaHCO3 
100mg 5.5mM Glucose 
715mg 30mM Hepes 
 84 
10.1.6 Incubation of liver slices for Glycogen Synthesis & Glycogen Content 
 
1. Warm up the water bath to 37°C 
2. Fill pre-incubation scintillation vials with 2ml of KRB-BSA buffer & place in the 
water bath.  
3. Fill basal scintillation vials with 2ml of KRB-BSA containing 0.2 µCi/ml D-[14C] 
glucose.  
4. Add insulin (100nM) to the remaining KRB-BSA containing D-[14C]glucose. 
5. Add this insulin/radiolabelled-glucose containing KRB buffer to the insulin-
stimulation scintillation vials.   
6. Ensure that all vials are capped with rubber stoppers and continuously 
gasified with carbogen (95% O2/5% CO2) at a steady rate.  
7. Extract a slice of liver weighing ~ 20mg (along the edges of the organ) being 
careful not to inflict damage to the tissue. Keep it moist at all times with ice-
cold PBS.  
8. Gently place the slice into the scintillation vial. *All slices are in pre-incubated 
for 1h. Subsequently, the slice is transferred to a second vial (basal or insulin-
stimulated in the presence of D-[14C] glucose) and incubated for another hour.  
9. At the end of the second hour, remove the slice from the vial and immediately 
dip in liquid nitrogen to freeze the reaction.  
10. Place the frozen slice in 500ul of 1N KOH for digestion for 30min @ 90°C. 
11. Keep 100ul for glycogen content (-80°C) and 400ul for glycogen synthesis 
assays (-20°C). 
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10.1.7  Glycogen Content Reagents 
 
Note: Adjust volumes accordingly depending on number of samples. 
 
Acetate Buffer (0.2M, pH 4.8) 
480µl  Acetic Acid (98%) 
975mg Sodium Acetate  
Complete to 100ml using ddH20. Adjust pH to 4.8 and store at 0-4°C. 
 
Amyloglucosidase Solution 
1mg  Amyloglucosidase Enzyme Protein Powder 
1ml  0.2M Acetate Buffer  
 
1N KOH (pH off the scale) 
5.61g  KOH 
Complete to 100ml using ddH2O. 
 
Triethanolamine (TRA) Buffer (0.3M TRA; 4.05mM MgSO4; 1N KOH, pH 7.5) 
 
5.6g  Triethanolamine  
100mg MgSO4 
12ml  1N KOH 
Complete to 100ml using ddH2O. Store at 0-4°C 
 
Ammonium Sulfate (3.2M)     
4.23g  (NH4)2SO4 
Complete to 10ml with ddH2O. 
 
Hexokinase/G6PDH Suspension 
500U (based on HK units – 125U/mg of protein. There is ~ 4mg of protein per 
vial.  
Re-suspend the lyophilized enzyme in 2ml of 3.2M Ammonium Sulfate (~ 
250U/ml).  
 
ATP-TRA Buffer (1mM ATP; 0.9mM NADP; 5ug/ml HK/G6PDH) 
6mg  ATP 
8mg  NADP 
10ml  TRA Buffer 
50µl  HK/G6PDH Suspension 
Note: Solution is stable for one week at 0-4°C. 
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10.1.8  Glycogen Content 
 
1. Transport the liver slice (weighing ~ 20-30mg) to a 1.5ml eppendorf and add 
500µl of 1M KOH. 
2. Incubate the sample on the heat block for 30min @ 90°C. 
3. 15min into the incubation period gently shake the eppendorf around once to 
ensure complete digestion.  
4. Extract 100µl for glycogen content and place in an eppendorf. The remaining 
400µl may be used for a glycogen synthesis assay if desired. 
5. Add 10% (v/v) of acetic acid 17.5M to digested tissue (maintains pH between 
4-5, ideally 4.8 which is optimum for hydrolysis of glycogen by 
amyloglucosidase). 
6. Add 500µl of acetate buffer (4.8 pH) with amyloglucosidase (0.5mg/ml). 
7. Incubate for 2h at 40°C with shaking or on bench overnight. 
8. Neutralize the solution with 1/16 (v/v) of NaOH (5N). pH should now be 7.37 
@ 25°C. 
9. Centrifuge for 5min @ 3000rpm. 
10.  Extract 400µl of the digested supernatant & add 1ml of ATP-TRA Buffer. 
11. Incubate for 30min on the bench. 
12. Gently vortex and extract 1ml and dispense into a plastic cuvette. 
13. Read the OD at 340nm. Note: (OD x 8.89) = umol of glucosyl units.  
14. Correct readings for tissue weight.  
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10.1.9 Glycogen Synthesis Reagents 
 
Note: Adjust volumes accordingly depending on number of samples. 
 
1N KOH (pH off the scale) 
5.61g  KOH 
Complete to 100ml using ddH2O 
 
Saturated Na2SO4 
Dissolve powdered Na2So4 in ddH2O until precipitation forms. Precipitate 
formation is a sign of saturation.  
 
Cold Ethanol 
Place 100% Ethanol in a 50ml falcon tube. Leave in -20°C. 
 
 
 
 
10.1.10 Glycogen Synthesis (Incorporation of D-[14C] glucose into Glycogen) 
 
1. Transport the liver slice (weighing ~ 20-30mg) to a 1.5ml eppendorf and add 
500µl of 1M KOH. 
2. Incubate the sample on the heat block for 30min @ 90°C. 
3. 15min into the incubation period gently shake the eppendorf around once to 
ensure complete digestion.  
4. Extract 400µl for glycogen content and place in a 2ml eppendorf. 
5. Add 100µl of carrier glycogen to each sample.  
6. Add 80µl of saturated Na2SO4 to each sample 
7. Add 1.2ml of cold ethanol 
8. Gently vortex each sample and incubate at -20°C overnight to allow 
precipitation. 
9. On the following day, check for precipitation and centrifuge the samples for 
20min @ 3000rpm.  
10.  Discard the resultant supernatant. 
11.  Dissolve the pellet in 500µl of ddH20. 
12.  Extract 400µl of sample and add to 5ml of scintillation fluid (ECOLITE+ liquid 
scintillation cocktail (MP Biomedicals Cat #01882475)) for counting. 
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10.1.11 Measuring Glucose 6-Phosphate using commercially available 
Calorimetric Kit  
 
Abcam, Cat # ab83426 
 
Sample Preparation (Ensure samples are always on ice throughout procedure) 
1. Weigh out 50mg of liver and homogenize in 2-3 volumes of ice cold PBS. 
2. Centrifuge the sample for 10min @ 12,000rpm (4°C). 
3. Extract the supernatant and place into a 10kDa molecular weight cut-off spin 
column (cat#UFC501008). 
4. Centrifuge the spin column for 1h @ 12,000rpm (4°C). 
5. Extract the lysate collected at the bottom of the column and dispense in a 
separate eppendorf. Keep on ice.    
 
Reaction mix Preparation  
Note: Prepare enough for the number of samples and standards you plan on 
running. 
 
 Reaction Mix Background 
Assay Buffer 46µl 48µl 
Enzyme Mix 2µl --- 
Substrate Mix 2µl 2µl 
 
 
Prepare Standard Curve & Run Samples 
1. Dilute the stock G6P standard (100nmol/ µl) to 1nmol/µl by adding 10µl of the 
stock to 990µl of ddH2O 
2. Add the diluted standard to a 96-well plate by pipetting 0,2,4,6,8,10µl into a 
series of wells.  
3. Add 1-50µl of sample to the wells.  
4. Use assay buffer to adjust volume of both samples and standards to 
50µl/well.  
5. Add 50µl of reaction mix to standards (excluding the 0) and samples. 
6. Add 50ul of background mix into the 0 standard (background). 
7. Incubate on the bench for 30min. Protect from light.  
8. Use the plate reader to measure at 450nm.  
9. Subtract the background from all standards and samples.  
10. Concentration = Ay/Sv, where Ay is the amount of G6P (nmol) in your sample 
and Sv is the volume (µl) of sample added to the well. 
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10.1.12 Complexation of Palmitic Acid 
 
1. Prepare 30mL of KRB Buffer (without glucose)  
2. Add 3.75g FA-free BSA (Sigma Cat# A3803) to get a 12.5% solution 
3. Heat to 50°C in water bath  
4. Take 1600mg palmitic acid (Sigma Cat# P-5585) to put into a 2mL 
eppendorf  
5. Dissolve palmitic acid with 100µl NaOH (10N) and vortex vigorously 
6. Add palmitic acid into preheated medium while stirring. (note; it will 
precipitate) 
7. Pour into falcon tube, protected from light  
8. Incubate in 50°C water bath for 4+ hours while shaking at 150-200rpm 
9. After the incubation period, filter solution to get chunks out using a 10mL 
syringe and sterile strainer  
10. pH to 7.4 
11. Aliquot solution and store at -20°C 
 
10.1.13 Determination of FFA using Wako Pure Chemicals HR Series NEFA –HR 
Kit 
 
1. Dissolve Reagent A into Solvent A 
• 4.1mg of Reagent A per 1mL of solvent A (calculate total volume 
you need for samples and standards) 
2. Add 0.5mL of Reagent A solution into each cuvette and incubate for 5 min 
at 37°C 
3. Dissolve Reagent B into Solvent B 
• 10.6mg of Reagent B per 1mL of solvent B 
4. Add 0.25mL of Reagent B solution into each cuvette and incubate for 5 
min at 37°C 
5. Read at OD 550nm  
 
Cuvette 1mEq/L 
NEFA 
Std 
(µL) 
H20 
(µL) 
Reagent 
A Sol. 
(mL) 
I 
N 
C 
U 
B 
A 
T 
E 
Reagent 
B Sol. 
(mL) 
I 
N 
C 
U 
B 
A 
T 
E 
Optical 
Density 
550nm 
NEFA 
Conc. 
(mEq/L) 
Blank - 12.5 0.5 0.25 0 (Ref) 0 
0 - 12.5 0.5 0.25 0 0 
Low 
Std 
6.25 6.25 0.5 0.25 read 0.5 
Mid Std 12.5 - 0.5 0.25 read 1.0 
High 
Std 
25 - 0.5 0.25 read 1.97 
Sample 12.5 - 0.5 0.25 read TBD 
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10.1.14 Incorporation of [1-14C] Palmitic acid into 14CO2 (Palmitate Oxidation) 
 
1. Warm up the water bath to 37°C 
2. Add 200mM of complexed palmitate and 0.2µCi/ml [1-14C] Palmitic acid to 
KRB buffer. 
3. Add 2ml of this buffer to the scintillation vial and incubate. 
4. Ensure that all vials are capped with rubber stoppers and continuously 
gasified with carbogen (95% O2/5% CO2) at a steady rate.  
5. Obtain a slice of liver weighing ~ 20mg (along the edges of the organ) being 
careful not to inflict damage to the tissue. Keep it moist at all times with ice-
cold PBS.  
6. Place the slice in the KRB-BSA medium containing [1-14C] palmitate  
7. Gasify using carbogen for 1 hour.  
8. After 1 hour, add 200µl (1:1, vol/vol) 2-phenylethylamine/methanol into a vial 
containing filter paper. 
9. Gently place this vial into the scintillation vial containing the sample. Reapply 
the rubber stopper and incubate for another hour with gasification using 
carbogen.  
10. Carefully, use a syringe to add 200µl of H2SO4 (5N) to the incubation medium 
making sure not to add any to the 2-phenylethylamine/methanol containing 
vial. The cap must remained closed while adding H2SO4 (5N). Incubate for 1h 
without gasification.  
11. Remove filter paper and place in a scintillation vial containing 10ml of 
scintillation fluid (ECOLITE+ liquid scintillation cocktail (MP Biomedicals Cat 
#01882475))  
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10.1.15 Measuring Triglyceride Content using commercially available 
Calorimetric Kit  
 
Note: This procedure can be done over one or two days.  
 
Materials 
• Triglyceride Quantification Kit (100 samples including 6 standards)  
(Cat# ab65336) 
• 5ml Tubes (1 tube/sample) 
• 5% NP40 
• ddH2O 
 
Day 1 – Sample Preparation  
 
1. Determine the number of samples to be assayed and make an appropriate 
amount of 5% NP40 (diluted in water) (1ml/sample).  
2. Add 100mg of tissue (liver) to 1ml of 5% NP40 in a 5ml tube. 
3. Heat the sample in the water bath for 10min @ 90°C. 
4. Homogenize the sample in the 5ml tubes.  
5. Heat the homogenized sample for 5min @ 90°C. 
6. Remove the tubes from the water bath and let them cool down to room 
temperature.  
7. Heat the sample once again for 5min @ 90°C. 
8. Centrifuge the samples for 2 min at max speed.  
9. Extract 20 µl for measuring protein content and store in an eppendorf.  
10.  Extract the remaining sample from the 5ml tubes and dispense into a 
separate eppendorf. (Be sure not to extract any insoluble material) 
11.  Store the samples at -80°C or continue procedure. 
 
Day 2 – Prepare Standard Curve and Run Samples. 
Note: Be sure to make room for 1 blank/condition.  
 
1. Allow samples to thaw.  
2. Vortex the samples and centrifuge them @13,200rpm for 10min.  
3. While vortexing, reconstitute the enzyme mix in 220µl of assay buffer. Also, 
reconstitute the lipase in 220µl of assay buffer. Make aliquots and store 
unused portion in -20°C.   
4. Dilute the stock standard (1mM) to 0.2mM by adding 100µl of the stock to 
400µl of assay buffer provided in the kit.  
5. Take a 96-well plate and start putting in the standards. Add 0µl, 10µl,  
      20µl, 30µl, 40 µl, and 50 µl of the 0.2mM standard in series.  
6. Use assay buffer to top up all standards to a final volume of 50µl. 
7. Dilute each of sample 10x by adding 10µl of sample to 90µl of  
      ddH2O. Mix well.  
8. For liver put 25 µl of the diluted sample per well. Top sample wells off to 
50µl/well by adding 25µl of assay buffer.  
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9. Add 2ul of lipase to every well INCLUDING the standards. For blanks (1 
blank/condition) add 2µl of assay buffer instead of the lipase. (This is the only 
difference between blanks and samples) 
10. Let the well incubate for 20 min (Gently shake for 2min. Use the remaining 
18min to make reaction mix). 
11.  Reaction mix (Light sensitive. Wrap in foil immediately. Store at room 
temperature) 
 
 
 
 
 
 
 
12.  Add 50µl of reaction mix to ALL wells including standards and blanks.  
13.  Shake the plate for 2min and incubate in a light-protected area for 1h.  
14.  Use the plate reader to read at 570nm. 
15.  Subtract your blanks from your samples.  
16.  Subtract absorbance of blank (standard 0) from all standards and samples.  
17. Calculate concentration.  
 
 
10.1.16	  Measuring	  Circulating	  Insulin	  by	  ELISA	  
1. Fast the animals for 14-hr then obtain a blood sample from the saphenous 
vein.        
2. Always keep blood on ice.  
3. Centrifuge the blood at for 10min @ 13,000rpm (4°C) 
4. Extract the plasma (supernatant) and place into another labeled eppendorf. 
Store at -80°C until you are ready to run the ELISA.  
5. When ready to assay, pre-warm all reagents of the EMD Millipore ELISA kit 
(Cat. # EZRMI-13K) to room temperature. 
6. Dilute the provided 10X wash buffer by 10-fold. 
7. Determine the number of samples to be assayed and place any extra 
microtiter strips in 2-8°C. 
8. Place the microtiter strips that you will be using in a plate holder and wash 3 
times with 300µl of diluted wash buffer. 
9. Remove buffer from wells by tapping lightly onto an absorbent surface DO 
NOT let the wells dry completely.  
10. Add 10µl of assay buffer to each blank & sample wells.  
11. Add 10µl of Matrix solution to blank, standard, and control wells.  
12. Add 10µl of 0.2, 0.5, 1, 2, 5 and 10 ng/mL insulin standards in ascending order.  
13. Add 10µl of quality control 1 & 2 into their own wells.  
14. Add 10µl of sample into the remaining wells.  
15. Add 80ul of detection antibody to all wells 
16. Seal the plate and incubate at room temperature for 2h on an orbital shaker 
17. Remove plate sealer and tap onto an absorbent surface to empty contents. 
 Reaction Mix 
Assay Buffer 46µl 
Triglyceride Probe 2µl 
Enzyme Mix 2µl 
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18. Wash the plate 3 times with 300µl of wash buffer by decanting after each 
wash.  
19. Add 100 µl of enzyme solution to each well. Seal with plate sealer and 
incubate for 30min at moderate speed on an orbital shaker.  
20. Remove the seal and decant the contents.  
21. Wash 6 times using diluted wash buffer making sure to decant contents after 
each wash.  
22. Add 100 µl of substrate solution to each well. Cover with plate sealer and 
shake for 20 min on orbital shaker.   
23. Add 100µl of stop solution to each well and mix well by hand. Ensure there 
are no bubbles and read using a plate reader at 450 and 590nm. Record 
absorbance. 
24. Calculate insulin concentrations as outlined in the manual.  
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10.2 Appendix B - Statement of Labor 
All experiments conducted in this study were carried out by Abinas 
Uthayakumar (AU), Diane Sepa-Kishi (DSK), Michelle Victoria Wu (MVW) and 
Arta Mohasas (AM). All were involved in the training of animals, collection of food 
intake and body weight data, extraction of tissues, IPGTT, IPPTT, and measuring 
palmitate oxidation. AU was responsible for measuring glycogen synthesis, 
glycogen content, and G6P with the help of AM. Moreover, AU conducted the 
western blots presented in this study. Due to the logistics of this experiment, AM 
quantified liver triglycerides, while DSK and MVW conducted experiments for 
lipolysis. 
 Dr. Rolando Ceddia is the primary investigator and supervisor of this 
project and this research was funded by the Natural Sciences and Engineering 
Research Council of Canada (NSERC) grant 311818-2011.  
 
